0001493152-17-012483.txt : 20171106 0001493152-17-012483.hdr.sgml : 20171106 20171106163142 ACCESSION NUMBER: 0001493152-17-012483 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171106 DATE AS OF CHANGE: 20171106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDICAL TRANSCRIPTION BILLING, CORP CENTRAL INDEX KEY: 0001582982 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] IRS NUMBER: 223832302 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36529 FILM NUMBER: 171179799 BUSINESS ADDRESS: STREET 1: 7 CLYDE ROAD STREET 2: SOMERSET CITY: SOMERSET STATE: NJ ZIP: 08873 BUSINESS PHONE: 7328735133 MAIL ADDRESS: STREET 1: 7 CLYDE ROAD STREET 2: SOMERSET CITY: SOMERSET STATE: NJ ZIP: 08873 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark one)

[X]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-36529

MEDICAL TRANSCRIPTION BILLING, CORP.

(Exact name of registrant as specified in its charter)

Delaware

22-3832302

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification Number)

7 Clyde Road

Somerset, New Jersey

08873

(Address of principal executive offices)

(Zip Code)

(732) 873-5133

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [ ]		Accelerated filer [ ]
Non-Accelerated filer [ ] (Do not check if a smaller reporting company)		Smaller reporting company [X]
		Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

At November 1, 2017, the registrant had 11,530,591 shares of common stock, par value $0.001 per share, outstanding.

INDEX

	Page

Forward Looking Statements	2

PART I. FINANCIAL INFORMATION


Item 1.	Condensed Consolidated Financial Statements (unaudited)
	Condensed Consolidated Balance Sheets at September 30, 2017 and December 31, 2016	3
	Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2017 and 2016	4
	Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2017 and 2016	5
	Condensed Consolidated Statement of Shareholders’ Equity for the nine months ended September 30, 2017	6
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2017 and 2016	7
	Notes to Condensed Consolidated Financial Statements	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	29
Item 4.	Controls and Procedures	29

	PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	31
Item 1A.	Risk Factors	31
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	31
Item 3.	Defaults Upon Senior Securities	31
Item 4.	Mine Safety Disclosures	31
Item 5.	Other Information	31
Item 6.	Exhibits	32
Signatures		32

Forward Looking Statements

Certain statements that we make from time to time, including statements contained in this Quarterly Report on Form 10-Q constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q are forward-looking statements. These statements, among other things, relate to our business strategy, goals and expectations concerning our products, future operations, prospects, plans and objectives of management. The words “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “will” and similar terms and phrases are used to identify forward-looking statements in this presentation. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this Quarterly Report on Form 10-Q include, without limitation, statements reflecting management’s expectations for future financial performance and operating expenditures (including our ability to continue as a going concern, to raise additional capital and to succeed in our future operations), expected growth, profitability and business outlook, increased sales and marketing expenses, and the expected results from the integration of our acquisitions.

Forward-looking statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. These factors include, among other things, the unknown risks and uncertainties that we believe could cause actual results to differ from these forward looking statements as set forth under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 31, 2017. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to:

	●	our ability to manage our growth, including acquiring, partnering with, and effectively integrating acquired businesses into our infrastructure;

	●	our ability to comply with covenants contained in our credit agreement with our senior secured lender, Silicon Valley Bank and other future debt facilities;

	●	our ability to retain our clients and revenue levels, including effectively migrating and keeping new clients acquired through business acquisitions and maintaining or growing the revenue levels of our new and existing clients;

	●	our ability to attract and retain key officers and employees, including Mahmud Haq and other personnel critical to growing our business and integrating of our newly acquired businesses;

	●	our ability to raise capital and obtain and maintain financing on acceptable terms;

	●	our ability to compete with other companies developing products and selling services competitive with ours, and who may have greater resources and name recognition than we have;

	●	our ability to maintain operations in Pakistan and Sri Lanka in a manner that continues to enable us to offer competitively priced products and services;

	●	our ability to keep and increase market acceptance of our products and services;

	●	our ability to keep pace with a rapidly changing healthcare industry;

	●	our ability to consistently achieve and maintain compliance with a myriad of federal, state, foreign, local, payor and industry requirements, regulations, rules and laws;

	●	our ability to protect and enforce intellectual property rights; and

	●	our ability to maintain and protect the privacy of client and patient information.

Although we believe that the expectations reflected in the forward-looking statements contained in this Quarterly Report on Form 10-Q are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of such forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this Quarterly Report on Form 10-Q.

You should read this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

All references to “MTBC,” “Medical Transcription Billing, Corp.,” “we,” “us,” “our” or the “Company” mean Medical Transcription Billing, Corp. and its subsidiaries, except where it is made clear that the term means only the parent company.

PART I. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (Unaudited)

MEDICAL TRANSCRIPTION BILLING, CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30,			December 31,
	2017			2016
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash	$	2,789,382		$	3,476,880
Accounts receivable - net of allowance for doubtful accounts of $268,000 and $156,000 at September 30, 2017 and December 31, 2016, respectively		3,535,673			4,330,901
Current assets - related party		25,203			13,200
Prepaid expenses and other current assets		758,785			618,501
Total current assets		7,109,043			8,439,482
Property and equipment - net		1,424,732			1,588,937
Intangible assets - net		2,997,211			5,833,706
Goodwill		12,263,943			12,178,868
Other assets		152,712			282,713
TOTAL ASSETS	$	23,947,641		$	28,323,706
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable	$	1,017,774		$	1,905,131
Accrued compensation		848,571			2,009,911
Accrued expenses		758,357			1,236,609
Deferred rent (current portion)		79,150			61,437
Deferred revenue (current portion)		52,145			41,666
Accrued liability to related party		16,614			16,626
Borrowings under line of credit		2,000,000			2,000,000
Current portion of long-term debt		-			2,666,667
Notes payable - other (current portion)		246,603			5,181,459
Contingent consideration (current portion)		537,736			535,477
Dividend payable		638,905			202,579
Total current liabilities		6,195,855			15,857,562
Long - term debt, net of discount and debt issuance costs		-			4,033,668
Notes payable - other		137,550			166,184
Deferred rent		371,273			433,186
Deferred revenue		30,001			26,673
Contingent consideration		131,957			394,072
Deferred tax liability		510,530			345,530
Total liabilities		7,377,166			21,256,875
COMMITMENTS AND CONTINGENCIES (Note 8)
SHAREHOLDERS' EQUITY:
Preferred stock, par value $0.001 per share - authorized 2,000,000 shares; issued and outstanding 929,299 and 294,656 shares at September 30, 2017 and December 31, 2016, respectively		929			295
Common stock, $0.001 par value - authorized 19,000,000 shares; issued 12,271,390 and 10,792,352 shares at September 30, 2017 and December 31, 2016, respectively; outstanding, 11,530,591 and 10,051,553 shares at September 30, 2017 and December 31, 2016, respectively		12,272			10,793
Additional paid-in capital		40,985,992			26,038,063
Accumulated deficit		(23,325,897	)		(17,944,230	)
Accumulated other comprehensive loss		(440,821	)		(376,090	)
Less: 740,799 common shares held in treasury, at cost at September 30, 2017 and December 31, 2016		(662,000	)		(662,000	)
Total shareholders' equity		16,570,475			7,066,831
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	23,947,641		$	28,323,706

See notes to condensed consolidated financial statements.

MEDICAL TRANSCRIPTION BILLING, CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2017			2016			2017			2016
NET REVENUE	$	7,513,592		$	5,341,002		$	23,518,416		$	15,663,687
OPERATING EXPENSES:
Direct operating costs		4,171,932			2,670,385			13,592,492			7,292,415
Selling and marketing		228,991			274,796			853,460			838,721
General and administrative		2,474,139			2,569,399			8,232,613			8,173,272
Research and development		249,045			174,876			843,294			575,059
Change in contingent consideration		-			(196,882	)		151,423			(607,978	)
Depreciation and amortization		664,441			1,118,282			3,637,131			3,536,940
Restructuring charges		-			-			275,628			-
Total operating expenses		7,788,548			6,610,856			27,586,041			19,808,429
OPERATING LOSS		(274,956	)		(1,269,854	)		(4,067,625	)		(4,144,742	)
OTHER:
Interest income		5,446			10,918			13,598			25,310
Interest expense		(678,103	)		(176,527	)		(1,242,672	)		(486,481	)
Other income (expense) - net		32,494			(13,933	)		107,364			(40,447	)
LOSS BEFORE INCOME TAXES		(915,119	)		(1,449,396	)		(5,189,335	)		(4,646,360	)
Income tax provision		65,000			45,309			192,332			126,236
NET LOSS	$	(980,119	)	$	(1,494,705	)	$	(5,381,667	)	$	(4,772,596	)

Preferred stock dividend		652,697			231,473			1,283,151			549,945
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$	(1,632,816	)	$	(1,726,178	)	$	(6,664,818	)	$	(5,322,541	)
Loss per common share:
Basic and diluted loss per share	$	(0.14	)	$	(0.17	)	$	(0.62	)	$	(0.53	)
Weighted-average basic and diluted shares outstanding		11,485,811			10,006,121			10,835,142			10,031,212

See notes to condensed consolidated financial statements.

MEDICAL TRANSCRIPTION BILLING, CORP.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2017			2016			2017			2016
NET LOSS	$	(980,119	)	$	(1,494,705	)	$	(5,381,667	)	$	(4,772,596	)
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX
Foreign currency translation adjustment (a)		(33,880	)		1,489			(64,731	)		12,305
COMPREHENSIVE LOSS	$	(1,013,999	)	$	(1,493,216	)	$	(5,446,398	)	$	(4,760,291	)

(a) No tax effect has been recorded as the Company recorded a valuation allowance against the tax benefit from its foreign currency translation adjustments.

See notes to condensed consolidated financial statements.

MEDICAL TRANSCRIPTION BILLING, CORP.

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (UNAUDITED)

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017

	Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Accumulated Other Comprehensive			Treasury (Common)			Total Shareholders'
	Shares		Amount		Shares		Amount		Capital			Deficit			Loss			Stock			Equity
Balance - January 1, 2017		294,656	$	295		10,792,352	$	10,793	$	26,038,063		$	(17,944,230	)	$	(376,090	)	$	(662,000	)	$	7,066,831
Net loss		-		-		-		-		-			(5,381,667	)		-			-			(5,381,667	)
Foreign currency translation adjustment		-		-		-		-		-			-			(64,731	)		-			(64,731	)
Issuance of stock under the Amended and Restated Equity Incentive Plan		24,750		25		266,663		267		(267	)		-			-			-			25
Stock-based compensation, net of cash settlements		-		-		-		-		907,160			-			-			-			907,160
Issuance of common stock, net of fees and expenses		-		-		1,000,000		1,000		1,971,065			-			-			-			1,972,065
Issuance of common stock held as contingent consideration		-		-		212,375		212		331,464			-			-			-			331,676
Issuance of preferred stock, net of fees and expenses		609,893		609		-		-		13,021,658			-			-			-			13,022,267
Preferred stock dividends		-		-		-		-		(1,283,151	)		-			-			-			(1,283,151	)
Balance - September 30, 2017		929,299	$	929		12,271,390	$	12,272	$	40,985,992		$	(23,325,897	)	$	(440,821	)	$	(662,000	)	$	16,570,475

See notes to condensed consolidated financial statements.

MEDICAL TRANSCRIPTION BILLING, CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016

	2017			2016
OPERATING ACTIVITIES:
Net loss	$	(5,381,667	)	$	(4,772,596	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		3,637,131			3,536,940
Deferred rent		(38,544	)		(28,032	)
Deferred revenue		13,807			(32,912	)
Provision for doubtful accounts		357,671			205,289
Provision for deferred income taxes		165,000			114,893
Foreign exchange (gain) loss		(27,145	)		72,360
Interest accretion and write-off of deferred financing costs		672,998			145,038
Non-cash restructuring charges		17,001			-
Stock-based compensation expense		333,854			765,595
Change in contingent consideration		151,423			(607,978	)
Acquisition settlements		-			(26,296	)
Changes in operating assets and liabilities:
Accounts receivable		437,557			(160,523	)
Other assets		107,532			211,651
Accounts payable and other liabilities		(1,754,255	)		90,843
Net cash used in operating activities		(1,307,637	)		(485,728	)
INVESTING ACTIVITIES:
Capital expenditures		(499,988	)		(319,870	)
Cash paid for acquisitions		(205,000	)		(1,425,000	)
Net cash used in investing activities		(704,988	)		(1,744,870	)
FINANCING ACTIVITIES:
Contingent consideration payments		(79,603	)		(153,799	)
Settlement of tax withholding obligations on stock issued to employees		(195,912	)		(8,500	)
Proceeds from issuance of common stock, net of placement costs		2,000,000			-
Proceeds from issuance of preferred stock, net of placement costs		13,484,552			1,270,528
Proceeds from long term debt, net of costs		-			1,908,141
Repayments of debt obligations		(7,626,088	)		(554,002	)
Repayment of Prudential obligation		(5,000,000	)		-
Proceeds from line of credit		7,000,000			6,000,000
Repayments of line of credit		(7,000,000	)		(6,000,000	)
Payment of registration statement and bank costs		(335,239	)		(119,406	)
Preferred stock dividends paid		(846,825	)		(506,603	)
Purchase of common shares		-			(546,145	)
Net cash provided by financing activities		1,400,885			1,290,214
EFFECT OF EXCHANGE RATE CHANGES ON CASH		(75,758	)		11,317
NET DECREASE IN CASH		(687,498	)		(929,067	)
CASH - Beginning of the period		3,476,880			8,039,562
CASH - End of period	$	2,789,382		$	7,110,495
SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES:
Vehicle financing obtained	$	30,746		$	189,725
Contingent consideration resulting from acquisitions	$	-		$	678,368
Dividends declared, not paid	$	638,905		$	202,578
Purchase of prepaid insurance through assumption of note	$	298,698		$	313,577
SUPPLEMENTAL INFORMATION - Cash paid during the period for:
Income taxes	$	9,513		$	32,816
Interest	$	599,950		$	321,530

See notes to condensed consolidated financial statements.

MEDICAL TRANSCRIPTION BILLING, CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF AND FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016 (UNAUDITED)

1. Organization and Business

Medical Transcription Billing, Corp. (and together with its subsidiaries “MTBC” or the “Company”) is a healthcare information technology company that offers an integrated suite of proprietary cloud-based electronic health records and practice management solutions, together with related business services, to healthcare providers. The Company’s integrated services are designed to help customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. The Company’s services include full-scale revenue cycle management, electronic health records, and other technology-driven practice management services for private and hospital-employed healthcare providers. MTBC has its corporate offices in Somerset, New Jersey and maintains account management teams in various US offices and operates facilities in Pakistan and Sri Lanka.

MTBC was founded in 1999 and incorporated under the laws of the State of Delaware in 2001. In 2004, MTBC formed MTBC Private Limited (or “MTBC Pvt. Ltd.”) a 99.9% majority-owned subsidiary of MTBC based in Pakistan. The remaining 0.01% of the shares of MTBC Pvt. Ltd. is owned by the founder and Chief Executive Officer of MTBC. MTBC formed MTBC-Europe Sp. z.o.o. (or “MTBC-Europe”), a wholly-owned subsidiary of MTBC based in Poland in 2015. In 2016, MTBC formed MTBC Acquisition Corp. (“MAC”), a Delaware corporation, in connection with its acquisition of substantially all the assets of MediGain, LLC and its subsidiary, Millennium Practice Management Associates, LLC (together “MediGain). MAC has a wholly-owned subsidiary in Sri Lanka, RCM MediGain Colombo, Pvt. Ltd. In conjunction with its continued growth of its offshore operations in Pakistan and Sri Lanka, in April 2017, MTBC began the winding down of its operations in India and Poland. These operations have been terminated and the subsidiaries are being liquidated.

2. Liquidity

The Company previously adopted FASB Accounting Standard Codification (“ASC”) Topic 205-40, Presentation of Financial Statements – Going Concern, which requires that management evaluate whether there are relevant conditions and events that, in the aggregate, raise substantial doubt about the entity’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that the financial statements are issued. Based upon the analysis set forth below, management believes there is no longer substantial doubt about the Company’s ability to continue as a going concern and to meet the obligations as they become due within the next twelve months.

As part of the evaluation, management considered that on September 30, 2017, the Company had $2.8 million of cash and had positive working capital of $913,000. The loss before income taxes was $915,000 for the three months ended September 30, 2017, of which $664,000 represents non-cash depreciation and amortization and $463,000 of non-cash financing costs, which were written off as a result of the termination of the Opus Bank (“Opus”) credit agreement.

During the second and third quarter of 2017, the Company raised a total of $15.0 million in net proceeds from a series of equity financings. In May 2017, the Company completed a registered direct offering of one million shares of its common stock at $2.30 per share, raising net proceeds of approximately $2.0 million. Between June and September 2017, the Company completed five public offerings of approximately 610,000 shares of its 11% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Preferred Stock”) at $25.00 per share, raising net proceeds of approximately $13.0 million.

These equity financings improved the financial position of the Company and allowed us to repay the amount owed to Prudential during the third quarter. As a result of the common and preferred stock offerings, the Company’s cash position and the working capital deficit at the end of the second quarter improved to positive net working capital of $913,000 at the end of the third quarter. At September 30, 2017, the total amount outstanding under the Opus credit line was $2 million and the Company has $2.8 million of cash. In October 2017, the Company entered into a new credit facility with Silicon Valley Bank (“SVB”) and repaid and terminated its previous facility with Opus. The SVB credit facility is a $5 million secured revolving line of credit where borrowings are based on a formula of 200% of repeatable revenue adjusted by an annualized attrition rate as defined in the credit facility agreement. Under the SVB credit facility agreement, the facility currently available to the Company is in excess of $4 million. Management continues to focus on the Company’s overall profitability, including growing revenue and managing expenses, and expects that these efforts will continue to enhance our liquidity and financial position. The Company forecasts that cash flow from operations over the next 12 months will be positive and provide sufficient liquidity to the Company. Management has based its expectations on assumptions that may prove to be wrong.

3. BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 8-03. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of items of a normal and recurring nature) necessary to present fairly the Company’s financial position as of September 30, 2017, the results of operations for the three and nine months ended September 30, 2017 and 2016 and cash flows for the nine months ended September 30, 2017 and 2016. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates.

The condensed consolidated balance sheet as of December 31, 2016 was derived from our audited consolidated financial statements. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2016, which are included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 31, 2017.

Recent Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently adopted and recently issued accounting pronouncements will not have a material impact on our consolidated financial position, results of operations and cash flows.

In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). The core principle of this amendment is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09, as amended by ASU 2015-14, ASU 2016-08, ASU 2016-10, ASU 2016-12 and ASU 2016-20, is effective for annual reporting periods beginning after December 15, 2017, and interim periods therein. These ASUs can be adopted either retrospectively to each prior reporting period presented or as a cumulative-effect adjustment as of the date of adoption. The Company plans to adopt Topic 606 using the modified retrospective method when it becomes effective for the Company in the first quarter of 2018. We have assigned internal resources to assist in the evaluation of the potential impacts of this amendment. Implementation efforts to date have included a review of revenue agreements and the performance obligations contained therein, and review of our commercial terms and practices across our revenue streams and a comparison of our current revenue recognition procedures to those required under Topic 606. While the Company is continuing to assess the effects of the amendment, management currently believes that the new guidance will not have a material impact on our revenue recognition policies, practices or systems. The Company is continuing to evaluate the effect that Topic 606 will have on its consolidated financial statements and related disclosures, and preliminary assessments are subject to change. We are in the process of finalizing the analysis of the requirements under Topic 606 and quantifying the effects if any, from the implementation which should be completed during the fourth quarter of 2017.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard will require organizations that lease assets — referred to as “lessees” — to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. Under the new guidance, a lessee will be required to recognize assets and liabilities for leases with lease terms of more than 12 months. Consistent with current GAAP, the recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. However, unlike current GAAP — which requires only capital leases to be recognized on the balance sheet — the new ASU will require both types of leases to be recognized on the balance sheet. The amendments in this ASU are effective for financial statements issued for annual periods beginning after December 15, 2018 with earlier adoption permitted. The Company is currently evaluating the impact of this new standard.

In January 2017, the FASB issued ASU No. 2017-01 Business Combinations (Topic 805): Clarifying the Definition of a Business. The ASU clarifies the definition of a business with the objective of adding guidance to assist companies and other reporting organizations with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or business. The amendments in this ASU provide a more robust framework to use in determining when a set of assets and activities is a business. The amendments provide more consistency in applying the guidance, reduce the costs of application, and make the definition of a business more operable. The ASU is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Upon adoption, the Company will apply the guidance in this ASU when evaluating whether acquired assets and activities constitute a business.

Also in January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment. The ASU modifies the accounting for goodwill impairment with the objective of simplifying the process of determining impairment levels. Specifically, the amendments in the ASU eliminate a step in the goodwill impairment test which requires companies to develop a hypothetical purchase price allocation when analyzing goodwill impairment. This eliminates the need for companies to estimate the fair value of individual existing assets and liabilities within a reporting unit. Instead, goodwill impairment will now be the amount by which a reporting unit’s total carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. All other aspects of the goodwill impairment test process have remained the same. The ASU is effective for annual periods beginning in the year 2020, with early adoption permitted for any impairment tests after January 1, 2017. The Company has elected to early adopt ASU 2017-04. There is currently no impact on the condensed consolidated financial statements as a result of this adoption.

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation: Scope of Modification Accounting (Topic 718), which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. An entity will account for the effects of a modification unless the fair value of the modified award is the same as the original award, the vesting conditions of the modified award are the same as the original award and the classification of the modified award as an equity instrument or liability instrument is the same as the original award. The guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. The update is to be adopted prospectively to an award modified on or after the adoption date. Early adoption is permitted. The Company is currently evaluating the effect of this update but does not believe it will have a material impact on its consolidated financial statements and related disclosures.

4. ACQUISITIONS

2017 Acquisition

Effective July 1, 2017, the Company purchased substantially all of the assets of Washington Medical Billing, LLC (“WMB”), a Washington limited liability company. In accordance with the asset purchase agreement, the Company agreed to a non-refundable initial payment (the “Initial Payment Amount”) of $205,000. In addition to the Initial Payment Amount, the Company agreed to pay the sellers 22%, 23% and 24% of revenue collected from the WMB accounts in the first, second and third year, respectively, subsequent to the acquisition date to the extent such amounts in the aggregate exceed the Initial Payment Amount (the “WMB Installment Payments”). The WMB Installment Payments are to be paid quarterly commencing October, 2017. Based on the Company’s revenue forecast, it does not appear that there will be any WMB Installment Payments and therefore the preliminary aggregate purchase price of WMB was determined to be $205,000.

The preliminary purchase price allocation for WMB was performed by the Company and is summarized as follows:

Customer relationships	$	120,000
Goodwill		85,000
	$	205,000

The WMB acquisition added additional clients to the Company’s customer base and, similar to previous acquisitions, broadened the Company’s presence in the healthcare technology industry through geographic expansion of its customer base and by increasing available customer relationship resources and specialized trained staff.

The weighted-average amortization period of the acquired intangible assets is three years.

Revenue earned from the WMB acquisition was approximately $165,000 during the quarter ended September 30, 2017.

2016 Acquisitions

On February 15, 2016 (the “GCB Closing Date”), the Company entered into an asset purchase agreement with Gulf Coast Billing, Inc. (“GCB”), pursuant to which the Company purchased substantially all of the assets of GCB. The aggregate final purchase price for GCB was $1,480,000 which consisted of cash of $1,250,000 and contingent consideration of $230,000. During the quarter ended June 30, 2017, an agreement was reached with GCB that no additional contingent consideration will be paid.

On May 2, 2016 (the “RMB Closing Date”), the Company entered into an asset purchase agreement with Renaissance Medical Billing, LLC (“RMB”), pursuant to which the Company purchased substantially all of the assets of RMB. In accordance with the RMB asset purchase agreement, the Company paid $175,000 in initial cash consideration (“RMB Initial Payment”), on the RMB Closing Date. In addition, the Company will pay RMB twenty-seven percent (27%) of the revenue earned and received from the acquired RMB accounts for three years, less the RMB Initial Payment which will be deducted in full from the required payments (the “RMB Installment Payments”) before any additional payment is made to the seller. The aggregate purchase price for RMB was $325,000 which consisted of cash of $175,000 and contingent consideration of $150,000. Through September 30, 2017, approximately $24,000 of contingent consideration payments have been made.

Effective July 1, 2016 (the “WFS Closing Date”), the Company entered into an asset purchase agreement with WFS Services, Inc. (“WFS”), pursuant to which the Company purchased substantially all of the assets of WFS. In accordance with the WFS asset purchase agreement, the Company did not pay any initial cash consideration on the WFS Closing Date but will make monthly payments of $5,000 for three years beginning July, 2016 subject to proportionate adjustment if annualized revenues decrease below a threshold specified in the APA. In addition, each quarter the Company will pay WFS fifty percent (50%) of Adjusted EBITDA, as defined in the WFS asset purchase agreement, generated from the WFS customer accounts acquired for three years. The aggregate purchase price of WFS was determined to be $298,000, which was recorded as contingent consideration. Through September 30, 2017, $60,000 of contingent consideration payments have been made.

On October 3, 2016, MAC acquired substantially all of the assets of MediGain. Since MediGain was in default of its obligations to Prudential prior to the acquisition, MAC purchased 100% of MediGain’s senior secured debt from Prudential.

The debt was collateralized by substantially all of MediGain’s assets, so immediately after purchasing the debt, MAC entered into a strict foreclosure agreement with MediGain transferring substantially all the assets (including accounts receivable, fixed assets, client relationships, and MediGain’s wholly-owned subsidiaries in India and Sri Lanka) to MAC in satisfaction of the outstanding obligations under the senior secured notes. The aggregate purchase price was $7 million which consisted of $2 million in cash paid at closing and $5 million, plus interest, which was paid during the third quarter of 2017.

MediGain, GCB, RMB and WFS are collectively referred to as the “2016 Acquisitions.” Revenue earned from the 2016 Acquisitions was approximately $4.1 million and $12.8 million during the three and nine months ended September 30, 2017, respectively.

Pro forma financial information (Unaudited)

The unaudited pro forma information below represents condensed consolidated results of operations as if the 2016 Acquisitions and the WMB Acquisition occurred on January 1, 2016. The pro forma information has been included for comparative purposes and is not indicative of results of operations of the Company would have had if the acquisitions occurred on the above date, nor is it necessarily indicative of future results.

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2017			2016			2017			2016
	($ in thousands, except per share data)
Total revenue	$	7,514		$	9,984		$	24,036		$	32,895
Net loss attributable to common shareholders	$	(1,581	)	$	(4,316	)	$	(6,584	)	$	(13,830	)
Net loss per common share	$	(0.14	)	$	(0.43	)	$	(0.61	)	$	(1.38	)

GOODWILL AND INTANGIBLE ASSETS-NET

Goodwill consists of the excess of the purchase price over the fair value of identifiable net assets of businesses acquired. The following is the summary of the changes to the carrying amount of goodwill for the nine months ended September 30, 2017 and the year ended December 31, 2016:

	September 30, 2017		December 31, 2016
Beginning gross balance	$	12,178,868	$	8,971,994
Acquisitions		85,075		3,206,874
Ending gross balance	$	12,263,943	$	12,178,868

Intangible assets include customer contracts and relationships and covenants not-to-compete acquired in connection with acquisitions, as well as software purchase and development costs and trademarks acquired. Intangible assets - net as of September 30, 2017 and December 31, 2016 consist of the following:

	September 30, 2017			December 31, 2016
Contracts and relationships acquired	$	16,491,300		$	16,371,375
Non-compete agreements		1,236,377			1,236,377
Other intangible assets		1,482,864			1,289,339
Total intangible assets		19,210,541			18,897,091
Less: Accumulated amortization		(16,213,330	)		(13,063,385	)
Intangible assets - net	$	2,997,211		$	5,833,706

Amortization expense was approximately $3.2 million for both the nine months ended September 30, 2017 and 2016, and $508,000 and $1.0 million for the three months ended September 30, 2017 and 2016, respectively. The weighted-average amortization period is three years.

As of September 30, 2017, future amortization expense scheduled to be expensed is as follows:

Years ending
December 31
2017 (three months)	$	493,264
2018		1,601,110
2019		827,033
2020		75,804
Total	$	2,997,211

NET LOss per COMMON share

The following table presents the weighted-average shares outstanding for basic and diluted net loss per share for the three and nine months ended September 30, 2017 and 2016:

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
		2017			2016			2017			2016
Basic and Diluted:
Net loss attributable to common shareholders	$	(1,632,816	)	$	(1,726,178	)	$	(6,664,818	)	$	(5,322,541	)
Weighted average shares applicable to common shareholders used in computing basic and diluted loss per share		11,485,811			10,006,121			10,835,142			10,031,212
Net loss attributable to common shareholders per share - Basic and Diluted	$	(0.14	)	$	(0.17	)	$	(0.62	)	$	(0.53	)

All unvested restricted share units (“RSUs”), the 200,000 warrants granted to Opus in 2015 and 2016 and the two million warrants issued during the second quarter of 2017 as part of the sale of common stock have been excluded from the above calculations as they were anti-dilutive. Vested RSUs and vested restricted shares have been included in the above calculations.

Debt

Opus — On September 2, 2015, the Company entered into a credit agreement with Opus. Opus extended a credit facility totaling $10 million to the Company, inclusive of $8 million of term loans and a $2 million revolving line of credit. The Company’s obligations to Opus were secured by substantially all of the Company’s domestic assets and 65% of the shares in its offshore subsidiaries. During October 2017, the Opus credit facility was replaced. See Note 15.

Interest expense in the consolidated statements of operations for both the three and nine months ended September 30, 2017 includes $463,000 of deferred financing costs which were written off as a result of the termination of the Opus credit agreement.

Prudential Deferred Purchase Price — During the current quarter, the entire amount due to Prudential of $5 million was paid, including $270,000 of accrued interest, which fully satisfied the amount owed.

Vehicle Financing Notes — The Company financed certain vehicle purchases both in the United States and in Pakistan. The vehicle financing notes have three to six year terms and were issued at current market rates.

Insurance Financing — The Company finances certain insurance purchases over the term of the policy life. The interest rate charged is 5.25%.

Commitments and Contingencies

Legal Proceedings — The Company is subject to legal proceedings and claims which have arisen in the ordinary course of business and have not been fully adjudicated. These actions, when ultimately concluded and determined, will not, in the opinion of management, have a material adverse effect upon the consolidated financial position, results of operations, or cash flows of the Company.

Leases — The Company leases certain office space and other facilities under operating leases expiring through 2021. Certain of these leases contain renewal options.

Future minimum lease payments under non-cancelable operating leases for office space as of September 30, 2017 are as follows:

Years Ending
December 31	Total
2017 (three months)	$	68,994
2018		304,357
2019		163,179
Total	$	536,530

Total rental expense, included in direct operating costs and general and administrative expense in the condensed consolidated statements of operations, amounted to approximately $690,000 and $581,000 for the nine months ended September 30, 2017 and 2016, respectively, and approximately $237,000 and $202,000 for the three months ended September 30, 2017 and 2016, respectively.

Acquisitions — In connection with some of the Company’s acquisitions, contingent consideration as of September 30, 2017 is payable in the form of cash with payment terms through 2019. Depending on the terms of the agreement, if the performance measures are not achieved, the Company may pay less than the recorded amount, and if the performance measures are exceeded, the Company may pay more than the recorded amount.

SHAREHOLDERS’ EQUITY TRANSACTIONS

In August 2017, the Company completed two public preferred stock offerings whereby a total of 60,195 shares of its Preferred Stock were sold at $25.00 per share. As a result of this sale, the Company received net proceeds of approximately $1.3 million. In September 2017, the Company completed two public preferred stock offerings whereby a total of 255,000 shares of its Preferred Stock were sold at $25.00 per share. As a result of this sale, the Company received net proceeds of approximately $5.6 million. Dividends on the Preferred Stock of $2.75 annually per share are cumulative from the date of issue and are payable each month when, as and if declared by the Company’s Board of Directors. As of September 30, 2017, the Board of Directors has declared monthly dividends on the Preferred Stock payable through November 2017.

Commencing on or after November 4, 2020, the Company may redeem, at its option, the Preferred Stock, in whole or in part, at a cash redemption price of $25.00 per share, plus all accrued and unpaid dividends to, but not including the redemption date. The Preferred Stock has no stated maturity, is not subject to any sinking fund or other mandatory redemption, and is not convertible into or exchangeable for any of the Company’s other securities. Holders of the Preferred Stock have no voting rights except for limited voting rights if dividends payable on the Preferred Stock are in arrears for eighteen or more consecutive or non-consecutive monthly dividend periods. If the Company were to liquidate, dissolve or wind up, the holders of the Preferred Stock will have the right to receive $25.00 per share, plus any accumulated and unpaid dividends to, but not including, the date of payment, before any payment is made to the holders of the common stock. The Preferred Stock is listed on the Nasdaq Capital Market under the trading symbol “MTBCP.”

10.

Related PARTIES

The Company had sales to a related party, a physician who is the wife of the CEO. Revenues from this customer were approximately $12,000 and $13,000 for the nine months ended September 30, 2017 and 2016, respectively, and approximately $4,000 and $5,000 for the three months ended September 30, 2017 and 2016, respectively. As of September 30, 2017 and December 31, 2016, the receivable balance due from this customer was approximately $1,500 and $1,600, respectively.

The Company is a party to a nonexclusive aircraft dry lease agreement with Kashmir Air, Inc. (“KAI”), which is owned by the CEO. The Company recorded an expense of approximately $96,000 for both the nine months ended September 30, 2017 and 2016 and approximately $32,000 for both the three months ended September 30, 2017 and 2016. As of September 30, 2017 and December 31, 2016, the Company had a liability outstanding to KAI of approximately $17,000, which is included in accrued liability to related party in the condensed consolidated balance sheets.

The Company leases its corporate offices, temporary housing for its foreign visitors and a storage facility in New Jersey and its backup operations center in Bagh, Pakistan, from the CEO. The related party rent expense for the nine months ended September 30, 2017 and 2016 was approximately $141,000 and $131,000, respectively, and $47,000 and $43,000 for the three months ended September 30, 2017 and 2016, respectively, and is included in direct operating costs and general and administrative expense in the condensed consolidated statements of operations. Current assets-related party on the consolidated balance sheets includes security deposits related to the leases of the Company’s corporate offices in the amount of approximately $13,000 as of both September 30, 2017 and December 31, 2016. The September 30, 2017 balance also includes prepaid rent paid to the CEO of approximately $12,000.

11.

STOCK-BASED COMPENSATION

In April 2014, the Company adopted the Medical Transcription Billing, Corp. 2014 Equity Incentive Plan (the “2014 Plan”), reserving a total of 1,351,000 shares of common stock for grants to employees, officers, directors and consultants. During April 2017, the 2014 Plan was amended whereby an additional 1,500,000 shares of common stock and 100,000 shares of Preferred Stock were added to the plan for future issuance. The name of the 2014 Plan was changed to the Amended and Restated Equity Incentive Plan (the “Incentive Plan”). As of September 30, 2017, 1,238,734 shares of common stock and 67,000 shares of Preferred Stock are available for grant. Permissible awards include incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units (“RSUs”), performance stock and cash-settled awards and other stock-based awards in the discretion of the Compensation Committee of the Board of Directors including unrestricted stock grants.

The equity based RSUs contain a provision in which the units shall immediately vest and become converted into common shares at the rate of one common share per RSU, immediately after a change in control, as defined in the award agreement.

During the third quarter of 2017, a total of 200,000 RSUs were granted equally to the four outside members of the Board of directors and a total of 300,000 RSUs were granted equally to three executive officers. The RSUs vest over the next two years, at six month intervals.

The Company recognizes compensation expense on a straight-line basis over the total requisite service period for the entire award. For stock awards classified as equity, the market price of our common or Preferred Stock on the date of grant is used in recording the fair value of the award. For stock awards classified as a liability, the earned amount is marked to market based on the end of period common stock price. The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2017 and 2016:

Stock-based compensation included in the Condensed	Three Months Ended September 30,					Nine Months Ended September 30,
Consolidated Statement of Operations:	2017			2016		2017		2016
Direct operating costs	$	1,705		$	3,571	$	7,162	$	8,909
General and administrative		124,789			131,077		318,870		731,690
Research and development		(675	)		3,767		7,822		6,910
Selling and marketing		-			5,378		-		18,086
Total stock-based compensation expense	$	125,819		$	143,793	$	333,854	$	765,595

The following table summarizes the RSU and restricted stock transactions related to the common stock under the Incentive Plan for the nine months ended September 30, 2017:

Outstanding and unvested at January 1, 2017	406,959
Granted	528,000
Vested	(327,159	)
Forfeited	(29,331	)
Outstanding and unvested at September 30, 2017	578,469

Of the total outstanding and unvested at September 30, 2017, 548,334 RSUs and restricted stock awards are classified as equity and 30,135 RSUs are classified as a liability.

The liability for the cash-settled awards was approximately $17,000 and $31,000 at September 30, 2017 and December 31, 2016, respectively, and is included in accrued compensation in the condensed consolidated balance sheets.

12.

INCOME TAXES

The deferred income tax provision for the nine months ended September 30, 2017 and 2016 primarily relates to the amortization of goodwill.

Although the Company is forecasting a return to profitability, it has incurred cumulative losses which make realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all Federal and state deferred tax assets as of September 30, 2017 and December 31, 2016. Some of the Federal NOL carry forward is currently subject to certain utilization limitations under Section 382 of the Internal Revenue Code.

The Company’s plan to repatriate earnings in its foreign locations to the United States requires that U.S. federal income taxes be provided on the Company’s earnings in those foreign locations. For state tax purposes, the Company’s foreign earnings generally are not taxed due to an exemption available in states where the Company currently transacts business.

13.

RESTRUCTURING CHARGES

During March 2017, the Company decided to close its operations in Poland and India. In connection with the closing of these subsidiaries, in the first quarter of 2017, the Company expensed approximately $276,000 of restructuring charges representing primarily employee severance costs, remaining lease and termination fees, disposal of property and equipment and professional fees. The remaining amounts to be paid of approximately $19,000 are included in accrued expenses in the condensed consolidated balance sheet as of September 30, 2017.

14.

FAIR VALUE OF FINANCIAL INSTRUMENTS

As of September 30, 2017 and December 31, 2016, the carrying amounts of receivables, accounts payable, accrued expenses and the amount due to Prudential (at December 31, 2016 only) approximated their estimated fair values because of the short term nature of these financial instruments.

Fair value measurements-Level 2

Our notes payable are carried at cost and approximate fair value since the interest rates being charged approximate market rates. The fair value of our term loans at December 31, 2016 was approximately $7.3 million. The Company’s outstanding borrowings under the line of credit with Opus had a carrying value of $2 million as of both September 30, 2017 and December 31, 2016. The fair value of the outstanding borrowings with Opus under the term loans at December 31, 2016 and the line of credit at December 31, 2016 and September 30, 2017 approximated the carrying value, as these borrowings bore interest based on prevailing variable market rates currently available at those dates. As a result, the Company categorizes these borrowings as Level 2 in the fair value hierarchy.

Contingent Consideration

The Company’s contingent consideration of approximately $670,000 and $930,000 as of September 30, 2017 and December 31, 2016, respectively, are Level 3 liabilities. The fair value of the contingent consideration at September 30, 2017 and December 31, 2016 was primarily driven by changes in revenue estimates related to the acquisitions during 2015 and 2016, the price of the Company’s common stock on the Nasdaq Capital Market (only for the December 31, 2016 contingent consideration amount), the passage of time and the associated discount rate. Due to the number of factors used to determine contingent consideration, it is not possible to determine a range of outcomes. Subsequent adjustments to the fair value of the contingent consideration liability will continue to be recorded in the Company’s results of operations until all contingencies are settled.

The following table provides a reconciliation of the beginning and ending balances for the contingent consideration measured at fair value using significant unobservable inputs (Level 3):

	Fair Value Measurement at Reporting Date Using Significant Unobservable Inputs, Level 3
	Nine Months Ended September 30,
	2017			2016
Balance - January 1,	$	929,549		$	1,172,508
Acquisitions		-			678,368
Change in fair value		151,423			(607,978	)
Settlement in the form of shares issued		(331,676	)		-
Payments		(79,603	)		(153,799	)
Balance - September 30,	$	669,693		$	1,089,099

15. SUBSEQUENT EVENT

During October 2017, the Opus credit facility was replaced with a $5 million revolving line of credit from SVB. Interest on the SVB revolving line of credit is charged at the prime rate plus 1.75%. There is also a fee of one-half of 1% for the unused portion of the credit line. Available borrowings are subject to 200% of repeatable revenue as defined, reduced by an annualized attrition rate. The debt is secured by all of the Company’s domestic assets and 65% of the shares in its offshore facilities. Future acquisitions are subject to approval by SVB.

In connection with the SVB debt agreement, the Company paid approximately $90,000 of fees upfront and issued warrants for SVB to purchase 125,000 shares of its common stock, and committed to pay an annual anniversary fee of $50,000 a year. The warrants have a strike price equal to the highest volume weighted average price per share for any five consecutive trading days during the thirty consecutive trading-day period commencing on the fifteenth trading day immediately preceding the date of the loan agreement. They have a five-year exercise window, piggyback registration and net exercise rights, and will be valued once the strike price is determined. The SVB credit agreement contains various covenants and conditions governing the revolving line of credit.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following is a discussion of our consolidated financial condition and results of operations for the three and nine months ended September 30, 2017 and 2016 and other factors that are expected to affect our prospective financial condition. The following discussion and analysis should be read together with our Condensed Consolidated Financial Statements and related notes beginning on page 4 of this Quarterly Report on Form 10-Q.

Some of the statements set forth in this section are forward-looking statements relating to our future results of operations. Our actual results may vary from the results anticipated by these statements. Please see “Forward-Looking Statements” on page 2 of this Quarterly Report on Form 10-Q.

Overview

MTBC is a healthcare information technology company that provides a fully integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers. Our integrated Software-as-a-Service (or SaaS) platform is designed to help our customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. We are able to deliver our leading solutions at very competitive prices because we leverage our proprietary software, which automates our workflows and increases efficiency, together with our highly educated and specialized offshore workforce of more than 1,700 team members at labor costs that we believe to be approximately one-tenth the cost of comparable U.S.

Our flagship offering, PracticePro, empowers healthcare practices with the core software and business services they need to address industry challenges on one unified SaaS platform. We deliver powerful, integrated and easy-to-use ‘big practice solutions’ to small and medium practices, which enable them to efficiently operate their businesses, manage clinical workflows and receive timely payment for their services. PracticePro consists of:

	●	Practice management software and related tools, which facilitate the day-to-day operation of a medical practice;
	●	Electronic health records (or EHR), which are easy to use, highly ranked, and allow our clients to reduce paperwork and qualify for government incentives;
	●	Revenue cycle management (or RCM) services, which include end-to-end medical billing, analytics, and related services; and
	●	Mobile Health (or mHealth) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services.

Adoption of our solutions requires little or no upfront expenditure by a provider. Additionally, our financial performance is linked directly to the financial performance of our clients because the vast majority of our revenues are based on a percentage of our clients’ collections. The standard fee for our complete, integrated, end-to-end solution is among the lowest in the industry.

During the third quarter of 2017, the Company introduced two new products – talkEHR, a voice enabled electronic health records (EHR) solution and EnrollmentPlus, a SaaS solution that streamlines the insurance enrollment workflow.

The Company has a clearinghouse service which allows clients to track claim status and includes services such as batch electronic claim and payment transaction clearing and web access for claim corrections. The Company also has an EDI service which provides a centralized electronic data interchange management system to record, manage and control the exchange of information. In addition, the Company has a printing and mailing operation.

Our growth strategy involves both acquisitive and organic growth. Both prongs of our strategy have yielded positive results for us historically.

With regard to our acquisition strategy, we believe that it is becoming increasingly difficult for traditional RCM companies to meet the growing technology and business service needs of healthcare providers without a significant investment in information technology infrastructure. The RCM service industry is highly fragmented, with many local and regional RCM companies serving small medical practices. We believe that the industry is ripe for consolidation and that we can achieve significant growth through acquisitions.

Our investment in sales and marketing during 2017 has helped us sign new customers which we expect will accelerate organic growth. First, we actively partner with industry participants who cross-market our services and otherwise provide referrals. Second, our newly launched talkEHR is a free product, but is designed to encourage users to upgrade to a revenue-generating, premium billing solution. Since the third quarter launch of talkEHR, more than 200 providers have signed-up for talkEHR and a few have already upgraded to our premium billing. As we move forward, we intend to continue to strategically promote talkEHR to new users, while encouraging providers who have already signed-up to actively use talkEHR in their day-to-day practice and upgrade to our premium billing solution. Third, a key part of our organic growth strategy for larger groups involves active attendance and participation in industry tradeshows.

Our offshore operations in Pakistan and Sri Lanka accounted for approximately 29% and 32% of total expenses for the nine months ended September 30, 2017 and 2016, respectively. A significant portion of those expenses were personnel-related costs (approximately 79% and 75% for the nine months ended September 30, 2017 and 2016, respectively). Because personnel-related costs are significantly lower in Pakistan and Sri Lanka than in the U.S. and many other offshore locations, we believe our offshore operations give us a competitive advantage over many industry participants. All of the medical billing companies that we have acquired use domestic labor or subcontractors from higher cost locations to provide all or a substantial portion of their services. We are able to achieve significant cost reductions as we shift these labor costs to our offshore operations.

On October 3, 2016, MTBC Acquisition, Corp. (“MAC”), a newly formed, a wholly-owned subsidiary of MTBC, acquired substantially all the medical billing business and assets of MediGain, LLC, a Texas limited liability company, and its subsidiary Millennium Practice Management Associates, LLC, a New Jersey limited liability company (“Millennium”) (together “MediGain”). In connection with this acquisition, MTBC expects to generate at least $10 million of annual revenue from the customers acquired. Although there is no assurance that the customers will remain with MTBC, the Company expects that this acquisition will continue to be accretive to earnings during the remainder of 2017. During the fourth quarter of 2016 and the first three quarters of 2017, we made significant progress at integrating the acquired operations with MTBC, but in the short term, we had a significant number of additional U.S.-based employees from MediGain. This cost, as well as costs from MediGain’s operations in India and its offshore subcontractors, impacted MTBC’s expenses during the fourth quarter of 2016 and the first quarter of 2017.

Key Performance Measures

We consider numerous factors in assessing our performance. Key performance measures used by management, including adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share, are non-GAAP financial measures, which we believe better enable management and investors to analyze and compare the underlying business results from period to period.

These non-GAAP financial measures should not be considered in isolation, or as a substitute for or superior to, financial measures calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Moreover, these non-GAAP financial measures have limitations in that they do not reflect all the items associated with the operations of our business as determined in accordance with GAAP. We compensate for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis, and we provide reconciliations from the most directly comparable GAAP financial measures to the non-GAAP financial measures. Our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

Adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share provide an alternative view of performance used by management and we believe that an investor’s understanding of our performance is enhanced by disclosing these adjusted performance measures.

Adjusted EBITDA excludes the following elements which are included in GAAP net income (loss):

	●	Income tax expense or the cash requirements to pay our taxes;
	●	Interest expense, or the cash requirements necessary to service interest on principal payments, on our debt;
	●	Foreign currency gains and losses and asset impairment charges and other non-operating expenditures;
	●	Stock-based compensation expense, including customer incentives and related fees, and cash-settled awards, based on changes in the stock price;
	●	Non-cash depreciation and amortization charges, and does not reflect any cash requirements for replacement for capital expenditures;
	●	Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees, exit costs related to terminating leases and other contractual agreements, costs related to specific transactions and restructuring charges arising from discontinued operations; and
	●	Changes in contingent consideration.

Set forth below is a presentation of our adjusted EBITDA for the three and nine months ended September 30, 2017 and 2016:

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2017			2016			2017			2016
	($ in thousands)
Net revenue	$	7,514		$	5,341		$	23,519		$	15,664

GAAP net loss	$	(980	)	$	(1,495	)	$	(5,382	)	$	(4,773	)

Provision for income taxes		65			45			192			126
Net interest expense		673			166			1,229			461
Foreign exchange / other expense		(24	)		14			(34	)		40
Stock-based compensation expense		126			194			334			816
Depreciation and amortization		664			1,118			3,637			3,537
Integration and transaction costs		85			285			636			609
Change in contingent consideration		-			(197	)		151			(608	)
Adjusted EBITDA	$	609		$	130		$	763		$	208

Adjusted operating income and adjusted operating margin exclude the following elements which are included in GAAP operating income (loss):

	●	Stock-based compensation expense, including customer incentives and related fees, and cash-settled awards, based on changes in the stock price;
	●	Amortization of purchased intangible assets;
	●	Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees, exit costs related to terminating leases and other contractual agreements, costs related to specific transactions and restructuring charges arising from discontinued operations; and
	●	Changes in contingent consideration.

Set forth below is a presentation of our adjusted operating income and adjusted operating margin, which represents adjusted operating income as a percentage of net revenue, for the three and nine months ended September 30, 2017 and 2016:

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2017			2016			2017			2016
	($ in thousands)
Net revenue	$	7,514		$	5,341		$	23,519		$	15,664

GAAP net loss	$	(980	)	$	(1,495	)	$	(5,382	)	$	(4,773	)
Provision for income taxes		65			45			192			126
Net interest expense		673			166			1,229			461
Other (income) expense - net		(32	)		14			(107	)		40
GAAP operating loss		(274	)		(1,270	)		(4,068	)		(4,146	)
GAAP operating margin		(3.6	%)		(23.8	%)		(17.3	%)		(26.5	%)

Stock-based compensation expense		126			194			334			816
Amortization of purchased intangible assets		419			949			2,881			3,077
Integration and transaction costs		85			285			636			609
Change in contingent consideration		-			(197	)		151			(608	)
Non-GAAP adjusted operating income	$	356		$	(39	)	$	(66	)	$	(252	)
Non-GAAP adjusted operating margin		4.7	%		(0.7	%)		(0.3	%)		(1.6	%)

Adjusted net income and adjusted net income per share exclude the following elements which are included in GAAP net income (loss):

	●	Foreign currency gains and losses and asset impairment charges and other non-operating expenditures;
	●	Stock-based compensation expense, including customer incentives and related fees, and cash-settled awards, based on changes in the stock price;
	●	Amortization of purchased intangible assets;
	●	Integration costs, such as severance amounts paid to employees from acquired businesses or transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees, exit costs related to terminating leases and other contractual agreements, costs related to specific transactions and restructuring charges arising from discontinued operations;
	●	Changes in contingent consideration; and
	●	Income tax expense resulting from the amortization of goodwill related to our acquisitions.

No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per share as the Company has sufficient carry forward losses to offset the applicable income taxes. The following table shows our reconciliation of GAAP net loss to non-GAAP adjusted net income for the three and nine months ended September 30, 2017 and 2016:

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2017			2016			2017			2016
	($ in thousands)
GAAP net loss	$	(980	)	$	(1,495	)	$	(5,382	)	$	(4,773	)

Foreign exchange / other expense		(24	)		14			(34	)		40
Stock-based compensation expense		126			194			334			816
Amortization of purchased intangible assets		419			949			2,881			3,077
Integration and transaction costs		85			285			636			609
Change in contingent consideration		-			(197	)		151			(608	)
Income tax expense related to goodwill		55			42			165			115
Non-GAAP adjusted net income	$	(319	)	$	(208	)	$	(1,249	)	$	(724	)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2017			2016			2017			2016
GAAP net loss per share	$	(0.14	)	$	(0.17	)	$	(0.62	)	$	(0.53	)

GAAP net loss per end-of-period share		(0.09	)		(0.15	)		(0.47	)		(0.46	)
Foreign exchange / other expense		0.00			0.00			0.00			0.00
Stock-based compensation expense		0.01			0.02			0.03			0.08
Amortization of purchased intangible assets		0.04			0.10			0.25			0.30
Integration and transaction costs		0.01			0.03			0.06			0.06
Change in contingent consideration		-			(0.02	)		0.01			(0.06	)
Income tax expense related to goodwill		0.00			0.00			0.01			0.01
Non-GAAP adjusted net income per share	$	(0.03	)	$	(0.02	)	$	(0.11	)	$	(0.07	)

End-of-period shares		11,530,591			10,295,370			11,530,591			10,295,370

For purposes of determining non-GAAP adjusted net income per share, the Company used the number of common shares outstanding at the end of September 30, 2017 and 2016, including shares which were issued but have not been settled, and considered contingent consideration. Accordingly, the end-of-period diluted common shares include 248,625 of contingently issuable shares at September 30, 2016. No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per common share as the Company has sufficient carry forward losses to offset the applicable income taxes.

Key Metrics

In addition to the line items in our consolidated financial statements, we regularly review the following key metrics to evaluate our business, measure our performance, identify trends in our business, prepare financial projections, make strategic business decisions, and assess market share trends and working capital needs. We believe information on these metrics is useful for investors to understand the underlying trends in our business.

Set forth below are our key operating and financial metrics for RCM customers using our platform, which excludes acquired customers who have not migrated to our platform as well as customers of our clearinghouse, EDI and other services. Revenue from practices using our proprietary platform accounted for approximately 47% of our revenue for the nine months ended September 30, 2017 and approximately 75% of our revenue for the nine months ended September 30, 2016.

First Pass Acceptance Rate: We define first pass acceptance rate as the percentage of claims submitted electronically by us, through our platform, to insurers and clearinghouses that are accepted on the first submission and are not rejected for reasons such as insufficient information or improper coding. Our first-time acceptance rate was approximately 96% for the twelve months ended September 30, 2017 and 2016, which compares favorably to the average of the top twelve payers of approximately 95%, as reported by the American Medical Association.

First Pass Resolution Rate: First pass resolution rate measures the percentage of primary claims that are favorably adjudicated and closed upon a single submission. Our first pass resolution rate was approximately 94% for the twelve months ended September 30, 2017 and 2016.

Days in Accounts Receivable: Days in accounts receivable measures the median number of days between the day a claim is submitted by us on behalf of our customer, and the date the claim is paid to our customer. Our clients’ median days in accounts receivable was approximately 36 days for primary care and 41 days for combined specialties for the twelve months ended September 30, 2017, and approximately 31 days for primary care and 39 days for combined specialties for the twelve months ended September 30, 2016, as compared to the national average of 36 and 40 days, respectively, as reported by the Medical Group Management Association in 2016.

Providers and Practices Served: As of September 30, 2017, we provided RCM and related services to approximately 2,600 providers (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services), representing approximately 740 practices. In addition, we served approximately 230 clients who were not medical practices, but are service organizations who serve the healthcare community. As of September 30, 2016, we served approximately 1,820 providers representing approximately 740 practices.

Sources of Revenue

Revenue: We primarily derive our revenues from revenue cycle management services, typically billed as a percentage of payments collected by our customers. This fee includes RCM as well as the ability to use our electronic health records and practice management software as part of the bundled fee. These payments accounted for approximately 89% of our revenues during both the three and nine months ended September 30, 2017, and 85% and 86% of our revenues during the three and nine months ended September 30, 2016, respectively.

We earned approximately 2% of our revenue from clearinghouse and EDI clients during both the three and nine months ended September 30, 2017, and 3% of our revenue from clearinghouse and EDI clients for both the three and nine months ended September 30, 2016. We earned approximately 5% and 4% of our revenue from printing and mailing operations during the three and nine months ended September 30, 2017, respectively, and 6% and 2% of our revenue from printing and mailing operations during the three and nine months ended September 30, 2016, respectively.

Operating Expenses

Direct Operating Costs. Direct operating cost consists primarily of salaries and benefits related to personnel who provide services to our customers, claims processing costs, and other direct costs related to our services. Costs associated with the implementation of new customers are expensed as incurred. The reported amounts of direct operating costs do not include depreciation and amortization, which are broken out separately in the condensed consolidated statements of operations.

Selling and Marketing Expense. Selling and marketing expense consists primarily of compensation and benefits, commissions, travel, advertising expenses.

Research and Development Expense. Research and development expense consists primarily of personnel-related costs and third-party contractor costs.

General and Administrative Expense. General and administrative expense consists primarily of personnel-related expense for administrative employees, including compensation, benefits, travel, occupancy and insurance, software license fees and outside professional fees.

Contingent Consideration. Contingent consideration represents the amount payable to the sellers of our acquisitions based on the achievement of defined performance measures contained in the purchase agreements. Contingent consideration is adjusted to fair value at the end of each reporting period.

Depreciation and Amortization Expense. Depreciation expense is charged using the straight-line method over the estimated lives of the assets ranging from three to five years. Amortization expense is charged on either an accelerated or on a straight-line basis over a period of three years for most intangible assets acquired in connection with acquisitions.

Interest and Other Income (Expense). Interest expense consists primarily of interest costs related to our working capital line of credit, term loans and amounts due in connection with acquisitions, offset by interest income. Our other income (expense) results primarily from foreign currency transaction gains (losses).

Income Tax. In preparing our condensed consolidated financial statements, we estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred income tax assets and liabilities. Although the Company is forecasting a return to profitability, it incurred cumulative losses which make realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all deferred tax assets as of September 30, 2017 and December 31, 2016.

Critical Accounting Policies and Estimates

We prepare our condensed consolidated financial statements in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions about future events, and apply judgments that affect the reported amounts of assets, liabilities, revenue, expense and related disclosures. We base our estimates, assumptions and judgments on historical experience, current trends and various other factors that we believe to be reasonable under the circumstances. The accounting estimates used in the preparation of our condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes. On a regular basis, we review our accounting policies, estimates, assumptions and judgments to ensure that our financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

The methods, estimates and judgments that we use in applying our accounting policies have a significant impact on our results of operations. There have been no material changes in our critical accounting policies and estimates from those described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 31, 2017.

Results of Operations

The following table sets forth our consolidated results of operations as a percentage of total revenue for the periods shown.

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Net revenue		100.0	%		100.0	%		100.0	%		100.0	%
Operating expenses:
Direct operating costs		55.5	%		50.0	%		57.8	%		46.6	%
Selling and marketing		3.0	%		5.1	%		3.6	%		5.4	%
General and administrative		32.9	%		48.1	%		35.0	%		52.2	%
Change in contingent consideration		0.0	%		(3.7	%)		0.6	%		(3.9	%)
Research and development		3.3	%		3.3	%		3.6	%		3.7	%
Depreciation and amortization		8.8	%		20.9	%		15.5	%		22.6	%
Restructuring charges		0.0	%		0.0	%		1.2	%		0.0	%
Total operating expenses		103.5	%		123.7	%		117.3	%		126.6	%

Operating loss		(3.5	%)		(23.7	%)		(17.3	%)		(26.6	%)

Interest expense - net		9.0	%		3.1	%		5.2	%		2.9	%
Other income (expense) - net		0.4	%		(0.3	%)		0.5	%		(0.3	%)
Loss before income taxes		(12.1	%)		(27.1	%)		(22.0	%)		(29.8	%)
Income tax provision		0.9	%		0.8	%		0.8	%		0.8	%
Net loss		(13.0	%)		(27.9	%)		(22.8	%)		(30.6	%)

Comparison of the three and nine months ended September 30, 2017 and 2016

Three Months Ended

September 30,

Change

Nine Months Ended
September 30,

Change

2017

2016

Amount

Percent

2017

2016

Amount

Percent

Revenue

7,513,592

5,341,002

2,172,590

23,518,416

15,663,687

7,854,729

Revenue. Total revenue of $7.5 million and $23.5 million for the three and nine months ended September 30, 2017 increased by $2.2 million or 41% and $7.9 million or 50% from revenue of $5.3 million and $15.7 million for the three and nine months ended September 30, 2016. Total revenue for the three and nine months ended September 30, 2017 included approximately $4.1 million and $12.8 million of revenue from customers we acquired from the 2016 Acquisitions (primarily MediGain), offset by attrition from customers.

	Three Months Ended September 30,					Change						Nine Months Ended September 30,					Change
	2017		2016			Amount			Percent			2017		2016			Amount			Percent
Direct operating costs	$	4,171,932	$	2,670,385		$	1,501,547			56	%	$	13,592,492	$	7,292,415		$	6,300,077			86	%
Selling and marketing		228,991		274,796			(45,805	)		(17	%)		853,460		838,721			14,739			2	%
General and administrative		2,474,139		2,569,399			(95,260	)		(4	%)		8,232,613		8,173,272			59,341			1	%
Research and development		249,045		174,876			74,169			42	%		843,294		575,059			268,235			47	%
Change in contingent consideration		-		(196,882	)		196,882			100	%		151,423		(607,978	)		759,401			125	%
Depreciation		156,237		128,743			27,494			21	%		484,429		369,204			115,225			31	%
Amortization		508,204		989,539			(481,335	)		(49	%)		3,152,702		3,167,736			(15,034	)		(0	%)
Restructuring charges		-		-			-			100	%		275,628		-			275,628			100	%
Total operating expenses	$	7,788,548	$	6,610,856		$	1,177,692			18	%	$	27,586,041	$	19,808,429		$	7,777,612			39	%

Direct Operating Costs. Direct operating costs of $4.2 million and $13.6 million for the three and nine months ended September 30, 2017, respectively, increased by $1.5 million or 56% and $6.3 million or 86% from direct operating costs of $2.7 million and $7.3 million for the three and nine months ended September 30, 2016, respectively. The MediGain acquisition increased salary costs by $912,000 and $3.3 million in the U.S. and $172,000 and $733,000 in India and Sri Lanka and operational outsourcing costs by $107,000 and $466,000 during the three and nine months ended September 30, 2017, respectively. Postage and delivery costs increased by $243,000 and $690,000 for the three and nine months ended September 30, 2017, respectively, primarily due to the acquisition of WFS. Salary and other related expenses in Pakistan increased by $332,000 and $1.1 million for the three and nine months ended September 30, 2017, respectively, as a result of the additional employees in Pakistan hired to service customers of the 2016 Acquisitions.

Selling and Marketing Expense. Selling and marketing expense of $229,000 and $853,000 for the three and nine months ended September 30, 2017, respectively, decreased by $46,000 or 17% and increased by $15,000 or 2% from selling and marketing expense of $275,000 and $839,000 for the three and nine months ended September 30, 2016, respectively.

General and Administrative Expense. General and administrative expense of $2.5 million for the three months ended September 30, 2017 decreased by $95,000 or 4% and for the nine months ended September 30, 2017, general and administrative expenses of $8.2 million increased by $59,000 or 1% compared to the same period in 2016. The reduction in general and administrative expense for the three months ended September 30, 2017 was primarily due to reduced salary costs and professional fees. The increase for the nine months ended September 30, 2017 compared to the same period in 2016 relates to additional salary costs from the MediGain acquisition. The integration of acquired businesses resulted in expense reductions related to the closing of offices and reducing third party expenses such as computer expenses, accommodation costs, office costs, and insurance expenses, which offset increased general and administrative resulting from the acquisitions.

Research and Development Expense. Research and development expense of $249,000 and $843,000 for the three and nine months ended September 30, 2017, respectively, increased by $74,000 or 42% and $268,000 or 47% from research and development expense of $175,000 and $575,000 for the three and nine months ended September 30, 2016, respectively, as a result of adding additional technical employees in Pakistan performing software development work.

Contingent Consideration. The change in contingent consideration of $151,000 during the nine months ended September 30, 2017 and $197,000 and $608,000 during the three and nine months ended September 30, 2016, respectively, relates to the change in the fair value of the contingent consideration from acquisitions. The expense for the nine months ended September 30, 2017 resulted from an increase in the price of the Company’s common stock for the Practicare shares that were held in escrow and released during June 2017.

Depreciation. Depreciation of $156,000 and $484,000 for the three and nine months ended September 30, 2017, respectively, increased by $27,000 or 21% and $115,000 or 31% from depreciation of $129,000 and $369,000 for the three and nine months ended September 30, 2016, respectively, primarily as a result of additional property and equipment purchases and the acquisition of property and equipment from the MediGain acquisition.

Amortization Expense. Amortization expense of $508,000 and $3.2 million for the three and nine months ended September 30, 2017, respectively, decreased by $481,000 and $15,000 from amortization expense of $990,000 and $3.2 million for the three and nine months ended September 30, 2016, respectively. This decrease during the three months ended September 30, 2017 resulted from the intangible assets acquired in connection with our 2014 acquisitions becoming fully amortized. The Company generally amortizes intangible assets over three years.

Restructuring Charges. In connection with the closing of its subsidiaries in Poland and India, as of March 31, 2017, the Company accrued approximately $276,000 of restructuring charges representing primarily employee severance costs, remaining lease and termination fees and professional fees. The Company anticipates that the liquidation will be completed in early 2018. A substantial amount of the work performed by these locations was transferred to the Pakistan facility. The Company will also be using an outside contractor to perform some of the work previously performed by the Indian subsidiary. As a result of closing the Poland and India facilities, the Company will no longer need to fund the costs of these facilities.

	Three Months Ended September 30,						Change						Nine Months Ended September 30,						Change
	2017			2016			Amount			Percent			2017			2016			Amount			Percent
Interest income	$	5,446		$	10,918		$	(5,472	)		(50	%)	$	13,598		$	25,310		$	(11,712	)		(46	%)
Interest expense		(678,103	)		(176,527	)		(501,576	)		(284	%)		(1,242,672	)		(486,481	)		(756,191	)		(155	%)
Other income (expense) - net		32,494			(13,933	)		46,427			333	%		107,364			(40,447	)		147,811			365	%
Income tax provision		65,000			45,309			19,691			43	%		192,332			126,236			66,096			52	%

Interest Income. Interest income of $5,000 and $14,000 for the three and nine months ended September 30, 2017, respectively, decreased by $5,000 or 50% and $12,000 or 46% from interest income of $11,000 and $25,000 for the three and nine months ended September 30, 2016, respectively. Interest income primarily represents late fees from customers.

Interest Expense. Interest expense of $678,000 and $1.2 million for the three and nine months ended September 30, 2017, respectively, increased by $502,000 or 284% and $756,000 or 155% from interest expense of $177,000 and $486,000 for the three and nine months ended September 30, 2016, respectively. This increase was primarily due to additional interest costs on borrowings under our term loans and line of credit and amounts related to the MediGain acquisition. Also, included in the 2017 interest expense is $463,000 of deferred financing costs related to the Opus credit agreement, which were written off as a result of the loans being paid off and the agreement terminated two years earlier than anticipated.

Other Income (Expense) - net. Other income - net was $32,000 and $107,000 for the three and nine months ended September 30, 2017, respectively, compared to other expense - net of $14,000 and $40,000 for the three and nine months ended September 30, 2016, respectively. Included in other income (expense) are foreign currency transaction gains (losses) primarily resulting from transactions in foreign currencies other than the functional currency. These transaction gains and losses are recorded in the condensed consolidated statements of operations related to the recurring measurement and settlement of such transactions. Other income for the nine months ended September 30, 2017 also includes $59,000 in cash received, net of obligations assumed, from the former owners of an acquired business as compensation for early termination of a client contract.

Income Tax Provision. There was a $65,000 and $192,000 provision for income taxes for the three and nine months ended September 30, 2017, respectively, an increase of $20,000 or 43% and $66,000 or 52% compared to the provision for income taxes of $45,000 and $126,000 for the three and nine months ended September 30, 2016, respectively. Included in the nine month ended September 30, 2017 and 2016 tax provisions are $165,000 and $115,000, respectively, deferred income tax provisions related to the amortization of goodwill. The increase in the income tax provisions is due to additional deferred income taxes relating to the Company’s acquisitions. The pre-tax loss decreased from $1.4 million for the three months ended September 30, 2016, to $915,000 and increased from $4.6 million to $5.2 million from the nine months ended September 30, 2016 to the same period in 2017. Although the Company is forecasting a return to profitability, it incurred three years of cumulative losses which make realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance was recorded against all deferred tax assets at September 30, 2017 and 2016.

Liquidity and Capital Resources

The Company had a cash balance of $2.8 million at September 30, 2017, and an outstanding balance of $2.0 million drawn on its revolving credit facility with Opus Bank (“Opus”).

During October 2017, the Company repaid and closed its Opus credit facility and replaced it with a $5 million revolving line of credit with Silicon Valley Bank (“SVB”). Borrowings under the SVB facility are based on amounts on 200% of repeatable revenue and adjusted for an annualized recurring churn rate. Under the SVB agreement, the facility currently available to the Company is in excess of $4.0 million.

During the nine months ended September 30, 2017, there was negative cash flow from operations of approximately $1.3 million, as the Company integrated its 2016 Acquisitions, the largest of which was MediGain. During the three months ended September 30, 2017, cash flow used by operations was $619,000. Included in this amount is $270,000 of interest paid to Prudential.

The following table summarizes our cash flows:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Net cash used in operating activities	$	(618,752	)	$	(169,023	)	$	(1,307,637	)	$	(485,728	)
Net cash used in investing activities		(359,773	)		(127,461	)		(704,988	)		(1,744,870	)
Net cash (used in) provided by financing activities		(1,990,525	)		783,673			1,400,885			1,290,214
Effect of exchange rate changes on cash		(52,054	)		4,385			(75,758	)		11,317
Net (decrease) increase in cash	$	(3,021,104	)	$	491,574		$	(687,498	)	$	(929,067	)

In September 2015, the Company secured a $10 million credit facility from Opus, including an $8 million term loan and a $2 million revolving line of credit. During October 2017, the credit facility with Opus was repaid and terminated, and replaced with a $5 million revolving line of credit from SVB. The Company has available in excess of $4.0 million under the SVB facility.

The Company had $2.8 million of cash and had positive working capital of $913,000 at September 30, 2017. The loss before income taxes was $915,000 for the three months ended September 30, 2017, of which $664,000 was non-cash depreciation and amortization. Additionally, the non-cash write-off of the deferred financing costs due to early the termination of the Opus credit agreement was $463,000.

Management achieved extensive expense reductions following the acquisition of MediGain in October 2016. The cost cutting included closing certain domestic and foreign facilities, eliminating reliance on subcontractors, and reducing non-essential personnel where work could be performed by offshore employees more cost-effectively. Direct operating and general and administrative costs decreased by $1.9 million and $1.8 million, respectively from the fourth quarter of 2016 to the third quarter of 2017. This represented reductions of 32% and 42%, respectively.

During the second and third quarter of 2017, the Company completed several equity financings totaling approximately $15.0 million in net proceeds.

Collectively, these developments dramatically improved the financial position of the Company. Management continues to focus on the Company’s overall profitability, including growing revenue and managing expenses, and expects that these efforts will continue to enhance our liquidity and financial position, allowing us to run our business, and comply with all bank covenants.

Operating Activities

Although revenue increased by $7.9 million for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016, operating expenses increased by $7.8 million for the same period primarily due to the acquisition of MediGain in the fourth quarter of 2016. Cash used in operating activities was $1.3 million during the nine months ended September 30, 2017, compared to $486,000 during the nine months ended September 30, 2016. The increase in the net loss of $609,000 included the following changes in non-cash items: additional depreciation and amortization of $100,000, additional provision for doubtful accounts of $152,000, additional interest accretion of $528,000 and a change in contingent consideration of $759,000, offset by a decrease in stock compensation expense of $432,000 and a change in working capital of $1.4 million.

Accounts receivable decreased by $438,000 for the nine months ended September 30, 2017, compared with an increase of $161,000 for the nine months ended September 30, 2016. Accounts payable, accrued compensation and accrued expenses decreased $1.8 million for the nine months ended September 30, 2017 (primarily due to the payment of liabilities assumed in connection with the MediGain acquisition and the reduction in the use of outside contractors) compared to an increase of $91,000 for the nine months ended September 30, 2016.

Investing Activities

Cash used in investing activities during the nine months ended September 30, 2017 was $705,000, a decrease of $1.0 million compared to $1.7 million during the nine months ended September 30, 2016. During the nine months ended September 30, 2017, $205,000 was paid in connection with the acquisition of WMB. During the nine months ended September 30, 2016, $1.25 million and $175,000 was paid in connection with the acquisitions of GCB and RMB, respectively.

Financing Activities

Cash provided by financing activities during the nine months ended September 30, 2017 was $1.4 million, compared to $1.3 million during the nine months ended September 30, 2016. Cash provided by financing activities during the nine months of 2017 includes $13.0 million of net proceeds from issuing approximately 610,000 shares of preferred stock, $2.0 million raised from issuing one million shares of common stock, offset by $7.6 million of repayments for debt obligations, a $5 million payment to Prudential and $847,000 of preferred stock dividends. Cash provided by financing activities for nine months ended September 30, 2016 included $2 million of additional borrowings on the Opus line of credit, offset by $554,000 repayment of debt obligations, $507,000 of preferred stock dividends and $546,000 of repurchases of common stock. Average borrowings from our revolving line of credit were $178,000 for the nine months ended September 30, 2016, compared to $1.4 million for the nine months ended September 30, 2017.

During October 2017, the Company replaced its Opus credit facility with a $5 million revolving line of credit from SVB. Borrowings under the credit facility are based on 200% of repeatable revenue reduced by an annualized attrition rate, as defined in the agreement. The Company currently has in excess of $4 million available on the SVB credit line.

Contractual Obligations and Commitments

We have contractual obligations under our line of credit and related to contingent consideration in connection with the acquisitions made in 2015 and 2016. We also maintain operating leases for property and certain office equipment. For additional information, see Contractual Obligations and Commitments under Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 31, 2017.

Off-Balance Sheet Arrangements

As of September 30, 2017 and 2016, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special-purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. Other than our operating leases for office space, computer equipment and other property, we do not engage in off-balance sheet financing arrangements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are a smaller reporting company as defined by 17C.F.R. 229.10(f)(1) and are not required to provide information under this item, pursuant to Item 305(e) of Regulation S-K.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, based on the 2013 framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2017 as required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

During the current quarter, we have finalized the integration and validation of controls for MediGain into the internal control practices for the Company.

Except as described above in the preceding paragraph, during the quarter ended September 30, 2017, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Part II. Other Information

Item 1. Legal Proceedings

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of our management, would individually or taken together have a material adverse effect on our business, operating results, financial condition or cash flows.

Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm and other factors.

Item 1A. Risk Factors

Pursuant to the instructions of Item 1A of Form 10-Q, a smaller reporting company is not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Purchases of Equity Securities

The Company is prohibited from paying dividends on its common stock without the consent of its senior lender, SVB.

Item 3. Defaults upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

Item 6. Exhibits

Exhibit Number		Exhibit Description

31.1		Certification of the Company’s Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), of the Securities Exchange Act of 1934, as amended.

31.2		Certification of the Company’s Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), of the Securities Exchange Act of 1934, as amended.

32.1*		Certification of the Company’s Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of the Company’s Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance

101.SCH		XBRL Taxonomy Extension Schema

101.CAL		XBRL Taxonomy Extension Calculation Linkbase

101.LAB		XBRL Taxonomy Extension Label Linkbase

101.PRE		XBRL Taxonomy Extension Presentation Linkbase

101.DEF		XBRL Taxonomy Extension Definition Linkbase

*The certifications on Exhibit 32 hereto are deemed not “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates them by reference.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Medical Transcription Billing, Corp.

November 6, 2017	By:	/s/ Mahmud Haq
Date		Mahmud Haq
		Chairman of the Board and Chief Executive Officer

November 6, 2017	By:	/s/ Bill Korn
Date		Bill Korn
		Chief Financial Officer

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mahmud Haq, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Medical Transcription Billing, Corp.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Medical Transcription Billing, Corp.

	By:	/s/ Mahmud Haq
		Mahmud Haq
		Chairman of the Board and Chief Executive Officer (Principal Executive Officer)
Dated:
November 6, 2017

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Bill Korn, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Medical Transcription Billing, Corp.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Medical Transcription Billing, Corp.

	By:	/s/ Bill Korn
		Bill Korn
		Chief Financial Officer (Principal Financial Officer )
Dated:
November 6, 2017

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Based on my knowledge, I, Mahmud Haq, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Medical Transcription Billing, Corp. on Form 10-Q for the quarterly period ended September 30, 2017 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-Q fairly presents in all material respects the financial condition and results of operations of Medical Transcription Billing, Corp.

	Medical Transcription Billing, Corp.

	By:	/s/ Mahmud Haq
		Mahmud Haq
		Chairman of the Board and Chief Executive Officer(Principal Executive Officer)
Dated:
November 6, 2017

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Based on my knowledge, I, Bill Korn, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Medical Transcription Billing, Corp. on Form 10-Q for the quarterly period ended September 30, 2017 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-Q fairly presents in all material respects the financial condition and results of operations of Medical Transcription Billing, Corp.

	Medical Transcription Billing, Corp.

	By:	/s/ Bill Korn
		Bill Korn
		Chief Financial Officer (Principal Financial Officer)
Dated:
November 6, 2017

EX-101.INS 6 mtbc-20170930.xml XBRL INSTANCE FILE 0001582982 2017-01-01 2017-09-30 0001582982 2016-12-31 0001582982 2017-09-30 0001582982 2016-01-01 2016-09-30 0001582982 us-gaap:PreferredStockMember 2016-12-31 0001582982 us-gaap:CommonStockMember 2016-12-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001582982 us-gaap:RetainedEarningsMember 2016-12-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001582982 us-gaap:TreasuryStockMember 2016-12-31 0001582982 MTBC:AssetPurchaseAgreementMember MTBC:RenaissanceMedicalBillingLLCMember 2016-05-02 0001582982 MTBC:AssetPurchaseAgreementMember MTBC:RenaissanceMedicalBillingLLCMember 2016-05-01 2016-05-02 0001582982 MTBC:GulfCoastBillingIncMember 2016-02-15 0001582982 MTBC:TwoThousandSixteenAcquisitionMember 2017-01-01 2017-09-30 0001582982 MTBC:OpusBankLoanMember MTBC:TotalMember 2015-09-02 0001582982 MTBC:OpusBankLoanMember MTBC:TermLoanMember 2015-09-02 0001582982 us-gaap:RevolvingCreditFacilityMember MTBC:OpusBankLoanMember 2015-09-02 0001582982 MTBC:OpusBankLoanMember 2017-01-01 2017-09-30 0001582982 MTBC:VehicleFinancingNotesMember 2017-01-01 2017-09-30 0001582982 us-gaap:ChiefExecutiveOfficerMember 2016-01-01 2016-09-30 0001582982 MTBC:PhysicianMember 2016-01-01 2016-09-30 0001582982 MTBC:PhysicianMember 2017-01-01 2017-09-30 0001582982 MTBC:PhysicianMember 2017-09-30 0001582982 MTBC:KashmirAirIncMember 2017-01-01 2017-09-30 0001582982 MTBC:KashmirAirIncMember 2017-09-30 0001582982 MTBC:TwoThousandFourteenEquityIncentivePlanMember MTBC:EmployeesOfficersDirectorsAndConsultantsMember 2014-04-30 0001582982 us-gaap:RestrictedStockUnitsRSUMember 2017-09-30 0001582982 MTBC:DirectOperatingCostsMember 2017-01-01 2017-09-30 0001582982 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-09-30 0001582982 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0001582982 us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-09-30 0001582982 MTBC:DirectOperatingCostsMember 2016-01-01 2016-09-30 0001582982 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-09-30 0001582982 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0001582982 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-09-30 0001582982 us-gaap:FairValueInputsLevel3Member 2017-01-01 2017-09-30 0001582982 us-gaap:FairValueInputsLevel3Member 2016-01-01 2016-09-30 0001582982 us-gaap:FairValueInputsLevel3Member 2016-09-30 0001582982 us-gaap:FairValueInputsLevel3Member 2017-09-30 0001582982 MTBC:KashmirAirIncMember 2016-01-01 2016-09-30 0001582982 us-gaap:ChiefExecutiveOfficerMember 2017-01-01 2017-09-30 0001582982 MTBC:AssetPurchaseAgreementMember MTBC:WFSServicesIncMember 2016-06-29 2016-07-01 0001582982 MTBC:AssetPurchaseAgreementMember MTBC:WFSServicesIncMember 2016-07-01 0001582982 MTBC:MediGainMember 2016-10-02 2016-10-03 0001582982 2016-09-30 0001582982 us-gaap:NoncompeteAgreementsMember 2016-12-31 0001582982 us-gaap:OtherIntangibleAssetsMember 2016-12-31 0001582982 us-gaap:PreferredStockMember 2017-01-01 2017-09-30 0001582982 us-gaap:PreferredStockMember 2017-09-30 0001582982 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0001582982 us-gaap:CommonStockMember 2017-09-30 0001582982 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0001582982 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001582982 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0001582982 us-gaap:RetainedEarningsMember 2017-09-30 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-09-30 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-30 0001582982 us-gaap:TreasuryStockMember 2017-01-01 2017-09-30 0001582982 us-gaap:TreasuryStockMember 2017-09-30 0001582982 2015-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-09-30 0001582982 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0001582982 2016-01-01 2016-12-31 0001582982 MTBC:PhysicianMember 2016-12-31 0001582982 MTBC:KashmirAirIncMember 2016-12-31 0001582982 us-gaap:ChiefExecutiveOfficerMember 2016-12-31 0001582982 us-gaap:FairValueInputsLevel2Member 2016-12-31 0001582982 us-gaap:FairValueInputsLevel3Member 2016-12-31 0001582982 us-gaap:FairValueInputsLevel3Member 2015-12-31 0001582982 us-gaap:ChiefExecutiveOfficerMember 2017-09-30 0001582982 us-gaap:FairValueInputsLevel2Member MTBC:OpusDebtMember 2017-09-30 0001582982 us-gaap:FairValueInputsLevel2Member MTBC:OpusDebtMember 2016-12-31 0001582982 MTBC:MediGainMember 2016-10-03 0001582982 MTBC:MtbcMember 2017-09-30 0001582982 2017-11-01 0001582982 2017-07-02 2017-09-30 0001582982 2016-07-02 2016-09-30 0001582982 MTBC:ElevenPercentageSeriesACumulativeRedeemablePreferredStockMember 2017-01-01 2017-09-30 0001582982 MTBC:ElevenPercentageSeriesACumulativeRedeemablePreferredStockMember 2017-09-30 0001582982 2017-01-01 2017-03-31 0001582982 2017-06-30 0001582982 MTBC:TwoThousandSixteenAcquisitionMember 2017-07-02 2017-09-30 0001582982 MTBC:OpusBankMember 2015-12-31 0001582982 MTBC:OpusBankMember 2016-12-31 0001582982 us-gaap:CommonStockMember 2017-05-01 2017-05-31 0001582982 us-gaap:CommonStockMember 2017-05-31 0001582982 MTBC:DirectOperatingCostsMember 2017-07-02 2017-09-30 0001582982 us-gaap:GeneralAndAdministrativeExpenseMember 2017-07-02 2017-09-30 0001582982 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-02 2017-09-30 0001582982 us-gaap:SellingAndMarketingExpenseMember 2017-07-02 2017-09-30 0001582982 MTBC:DirectOperatingCostsMember 2016-07-02 2016-09-30 0001582982 us-gaap:GeneralAndAdministrativeExpenseMember 2016-07-02 2016-09-30 0001582982 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-02 2016-09-30 0001582982 us-gaap:SellingAndMarketingExpenseMember 2016-07-02 2016-09-30 0001582982 MTBC:AssetPurchaseAgreementMember MTBC:WashingtonMedicalBillingLLCMember 2017-07-01 0001582982 MTBC:WashingtonMedicalBillingLLCMember MTBC:FirstYearMember MTBC:RevenueCollectedFromWMBAccountsMember 2017-06-29 2017-07-01 0001582982 MTBC:WashingtonMedicalBillingLLCMember MTBC:SecondYearMember MTBC:RevenueCollectedFromWMBAccountsMember 2017-06-29 2017-07-01 0001582982 MTBC:WashingtonMedicalBillingLLCMember MTBC:ThirdYearMember MTBC:RevenueCollectedFromWMBAccountsMember 2017-06-29 2017-07-01 0001582982 MTBC:PhysicianMember 2017-07-02 2017-09-30 0001582982 MTBC:PhysicianMember 2016-07-02 2016-09-30 0001582982 MTBC:KashmirAirIncMember 2017-07-02 2017-09-30 0001582982 MTBC:KashmirAirIncMember 2016-07-02 2016-09-30 0001582982 us-gaap:ChiefExecutiveOfficerMember 2017-07-02 2017-09-30 0001582982 us-gaap:ChiefExecutiveOfficerMember 2016-07-02 2016-09-30 0001582982 MTBC:AmendedAndRestatedEquityIncentivePlanMember us-gaap:CommonStockMember 2017-04-28 2017-04-30 0001582982 MTBC:AmendedAndRestatedEquityIncentivePlanMember us-gaap:SeriesAPreferredStockMember 2017-04-28 2017-04-30 0001582982 MTBC:AmendedAndRestatedEquityIncentivePlanMember us-gaap:CommonStockMember 2017-09-30 0001582982 MTBC:AmendedAndRestatedEquityIncentivePlanMember us-gaap:PreferredStockMember 2017-09-30 0001582982 MTBC:MediGainMember 2017-07-02 2017-09-30 0001582982 MTBC:WMBMember 2017-09-30 0001582982 MTBC:ContractsAndRelationshipsAcquiredMember 2017-09-30 0001582982 us-gaap:NoncompeteAgreementsMember 2017-09-30 0001582982 us-gaap:OtherIntangibleAssetsMember 2017-09-30 0001582982 MTBC:ContractsAndRelationshipsAcquiredMember 2016-12-31 0001582982 us-gaap:PreferredStockMember 2017-08-01 2017-08-31 0001582982 us-gaap:PreferredStockMember 2017-08-31 0001582982 us-gaap:PreferredStockMember MTBC:TwoPublicPreferredStockOfferingsMember 2017-09-01 2017-09-30 0001582982 MTBC:TwoThousandFourteenEquityIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember MTBC:BoardofDirectorsMember 2017-07-02 2017-09-30 0001582982 MTBC:TwoThousandFourteenEquityIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember MTBC:ThreeExecutiveOfficersMember 2017-07-02 2017-09-30 0001582982 us-gaap:SubsequentEventMember MTBC:OpusCreditFacilityMember 2017-10-31 0001582982 us-gaap:SubsequentEventMember MTBC:OpusCreditFacilityMember us-gaap:PrimeRateMember 2017-10-31 0001582982 us-gaap:SubsequentEventMember MTBC:OpusCreditFacilityMember 2017-10-01 2017-10-31 0001582982 MTBC:SVBCreditFacilityAgreementMember MTBC:OctoberTwoThousandAndSeventeenMember 2017-09-30 0001582982 MTBC:OpusCreditFacilityMember 2017-09-30 0001582982 us-gaap:SubsequentEventMember MTBC:SVBDebtAgreementMember 2017-10-01 2017-10-31 0001582982 us-gaap:SubsequentEventMember MTBC:SVBDebtAgreementMember 2017-10-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure MEDICAL TRANSCRIPTION BILLING, CORP 10-Q 2017-09-30 false --12-31 Smaller Reporting Company Q3 MTBC

-5381667

-4772596

-5381667

-980119

-1494705

28323706

23947641

12178868

12263943

85000

8439482

7109043

15857562

6195855

535477

537736

670000

930000

156000

268000

0.001

2000000

294656

929299

294656

929299

0.001

19000000

10792352

12271390

10051553

11530591

740799

-5446398

-4760291

-1013999

-1493216

-64731

12305

-33880

1489

205000

1425000

0.0001

0.999

10000000

8000000

2000000

5000000

175000

1250000

325000

1480000

298000

150000

230000

298000

P3Y

5000

The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2017 and 2016:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Stock-based compensation included in the Condensed </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Three Months Ended September 30,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Nine Months Ended September 30,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr> <td style="vertical-align: top; line-height: 115%">Consolidated Statement of Operations:</td> <td style="vertical-align: bottom; text-align: center; line-height: 115%"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="vertical-align: bottom; text-align: center; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: center; line-height: 115%"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="vertical-align: bottom; text-align: center; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: center; line-height: 115%"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="vertical-align: bottom; text-align: center; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: center; line-height: 115%"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="vertical-align: bottom; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%; line-height: 115%">Direct operating costs</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">1,705</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">3,571</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">7,162</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">8,909</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">General and administrative</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">124,789</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">131,077</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">318,870</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">731,690</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Research and development</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(675</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3,767</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">7,822</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6,910</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Selling and marketing</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">5,378</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">18,086</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total stock-based compensation expense</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">125,819</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">143,793</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">333,854</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">765,595</td> <td style="line-height: 115%"> </td></tr> </table>

The following table summarizes the RSU and restricted stock transactions related to the common stock under the Incentive Plan for the nine months ended September 30, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 76%; line-height: 115%">Outstanding and unvested at January 1, 2017</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 21%; text-align: right; line-height: 115%">406,959</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">528,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Vested</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(327,159</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Forfeited</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(29,331</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Outstanding and unvested at September 30, 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">578,469</td> <td style="line-height: 115%"> </td></tr> </table>

The following table provides a reconciliation of the beginning and ending balances for the contingent consideration measured at fair value using significant unobservable inputs (Level 3):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Fair Value Measurement at Reporting Date Using Significant Unobservable Inputs, Level 3</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Nine Months Ended September 30,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 115%">Balance - January 1,</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">929,549</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">1,172,508</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Acquisitions</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">678,368</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Change in fair value</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">151,423</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(607,978</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Settlement in the form of shares issued</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(331,676</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Payments</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(79,603</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(153,799</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Balance - September 30,</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">669,693</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">1,089,099</td> <td style="line-height: 115%"> </td></tr> </table>

192332

126236

65000

45309

-5189335

-4646360

-915119

-1449396

107364

-40447

32494

-13933

1242672

486481

678103

176527

13598

25310

5446

10918

-4067625

-4144742

-274956

-1269854

27586041

19808429

7788548

6610856

843294

575059

249045

174876

8232613

8173272

2474139

2569399

853460

838721

228991

274796

13592492

7292415

4171932

2670385

23518416

15663687

7513592

5341002

-6664818

-5322541

-1632816

-1726178

1283151

549945

652697

231473

10835142

10031212

11485811

10006121

1. Organization and Business   Medical Transcription Billing, Corp. (and together with its subsidiaries “MTBC” or the “Company”) is a healthcare information technology company that offers an integrated suite of proprietary cloud-based electronic health records and practice management solutions, together with related business services, to healthcare providers. The Company’s integrated services are designed to help customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. The Company’s services include full-scale revenue cycle management, electronic health records, and other technology-driven practice management services for private and hospital-employed healthcare providers. MTBC has its corporate offices in Somerset, New Jersey and maintains account management teams in various US offices and operates facilities in Pakistan and Sri Lanka.   MTBC was founded in 1999 and incorporated under the laws of the State of Delaware in 2001. In 2004, MTBC formed MTBC Private Limited (or “MTBC Pvt. Ltd.”) a 99.9% majority-owned subsidiary of MTBC based in Pakistan. The remaining 0.01% of the shares of MTBC Pvt. Ltd. is owned by the founder and Chief Executive Officer of MTBC. MTBC formed MTBC-Europe Sp. z.o.o. (or “MTBC-Europe”), a wholly-owned subsidiary of MTBC based in Poland in 2015. In 2016, MTBC formed MTBC Acquisition Corp. (“MAC”), a Delaware corporation, in connection with its acquisition of substantially all the assets of MediGain, LLC and its subsidiary, Millennium Practice Management Associates, LLC (together “MediGain). MAC has a wholly-owned subsidiary in Sri Lanka, RCM MediGain Colombo, Pvt. Ltd. In conjunction with its continued growth of its offshore operations in Pakistan and Sri Lanka, in April 2017, MTBC began the winding down of its operations in India and Poland. These operations have been terminated and the subsidiaries are being liquidated.

2. Liquidity   The Company previously adopted FASB Accounting Standard Codification (“ASC”) Topic 205-40, Presentation of Financial Statements – Going Concern, which requires that management evaluate whether there are relevant conditions and events that, in the aggregate, raise substantial doubt about the entity’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that the financial statements are issued. Based upon the analysis set forth below, management believes there is no longer substantial doubt about the Company’s ability to continue as a going concern and to meet the obligations as they become due within the next twelve months.   As part of the evaluation, management considered that on September 30, 2017, the Company had $2.8 million of cash and had positive working capital of $913,000. The loss before income taxes was $915,000 for the three months ended September 30, 2017, of which $664,000 represents non-cash depreciation and amortization and $463,000 of non-cash financing costs, which were written off as a result of the termination of the Opus Bank (“Opus”) credit agreement.   During the second and third quarter of 2017, the Company raised a total of $15.0 million in net proceeds from a series of equity financings. In May 2017, the Company completed a registered direct offering of one million shares of its common stock at $2.30 per share, raising net proceeds of approximately $2.0 million. Between June and September 2017, the Company completed five public offerings of approximately 610,000 shares of its 11% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Preferred Stock”) at $25.00 per share, raising net proceeds of approximately $13.0 million.   These equity financings improved the financial position of the Company and allowed us to repay the amount owed to Prudential during the third quarter. As a result of the common and preferred stock offerings, the Company’s cash position and the working capital deficit at the end of the second quarter improved to positive net working capital of $913,000 at the end of the third quarter. At September 30, 2017, the total amount outstanding under the Opus credit line was $2 million and the Company has $2.8 million of cash. In October 2017, the Company entered into a new credit facility with Silicon Valley Bank (“SVB”) and repaid and terminated its previous facility with Opus. The SVB credit facility is a $5 million secured revolving line of credit where borrowings are based on a formula of 200% of repeatable revenue adjusted by an annualized attrition rate as defined in the credit facility agreement. Under the SVB credit facility agreement, the facility currently available to the Company is in excess of $4 million. Management continues to focus on the Company’s overall profitability, including growing revenue and managing expenses, and expects that these efforts will continue to enhance our liquidity and financial position. The Company forecasts that cash flow from operations over the next 12 months will be positive and provide sufficient liquidity to the Company. Management has based its expectations on assumptions that may prove to be wrong.

4. ACQUISITIONS   2017 Acquisition   Effective July 1, 2017, the Company purchased substantially all of the assets of Washington Medical Billing, LLC (“WMB”), a Washington limited liability company. In accordance with the asset purchase agreement, the Company agreed to a non-refundable initial payment (the “Initial Payment Amount”) of $205,000. In addition to the Initial Payment Amount, the Company agreed to pay the sellers 22%, 23% and 24% of revenue collected from the WMB accounts in the first, second and third year, respectively, subsequent to the acquisition date to the extent such amounts in the aggregate exceed the Initial Payment Amount (the “WMB Installment Payments”). The WMB Installment Payments are to be paid quarterly commencing October, 2017. Based on the Company’s revenue forecast, it does not appear that there will be any WMB Installment Payments and therefore the preliminary aggregate purchase price of WMB was determined to be $205,000.   The preliminary purchase price allocation for WMB was performed by the Company and is summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%; line-height: 115%">Customer relationships</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 25%; text-align: right; line-height: 115%">120,000</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Goodwill</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">85,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">205,000</td> <td style="line-height: 115%"> </td></tr> </table>   The WMB acquisition added additional clients to the Company’s customer base and, similar to previous acquisitions, broadened the Company’s presence in the healthcare technology industry through geographic expansion of its customer base and by increasing available customer relationship resources and specialized trained staff.   The weighted-average amortization period of the acquired intangible assets is three years.   Revenue earned from the WMB acquisition was approximately $165,000 during the quarter ended September 30, 2017.   2016 Acquisitions   On February 15, 2016 (the “GCB Closing Date”), the Company entered into an asset purchase agreement with Gulf Coast Billing, Inc. (“GCB”), pursuant to which the Company purchased substantially all of the assets of GCB. The aggregate final purchase price for GCB was $1,480,000 which consisted of cash of $1,250,000 and contingent consideration of $230,000. During the quarter ended June 30, 2017, an agreement was reached with GCB that no additional contingent consideration will be paid.   On May 2, 2016 (the “RMB Closing Date”), the Company entered into an asset purchase agreement with Renaissance Medical Billing, LLC (“RMB”), pursuant to which the Company purchased substantially all of the assets of RMB. In accordance with the RMB asset purchase agreement, the Company paid $175,000 in initial cash consideration (“RMB Initial Payment”), on the RMB Closing Date. In addition, the Company will pay RMB twenty-seven percent (27%) of the revenue earned and received from the acquired RMB accounts for three years, less the RMB Initial Payment which will be deducted in full from the required payments (the “RMB Installment Payments”) before any additional payment is made to the seller. The aggregate purchase price for RMB was $325,000 which consisted of cash of $175,000 and contingent consideration of $150,000. Through September 30, 2017, approximately $24,000 of contingent consideration payments have been made.   Effective July 1, 2016 (the “WFS Closing Date”), the Company entered into an asset purchase agreement with WFS Services, Inc. (“WFS”), pursuant to which the Company purchased substantially all of the assets of WFS. In accordance with the WFS asset purchase agreement, the Company did not pay any initial cash consideration on the WFS Closing Date but will make monthly payments of $5,000 for three years beginning July, 2016 subject to proportionate adjustment if annualized revenues decrease below a threshold specified in the APA. In addition, each quarter the Company will pay WFS fifty percent (50%) of Adjusted EBITDA, as defined in the WFS asset purchase agreement, generated from the WFS customer accounts acquired for three years. The aggregate purchase price of WFS was determined to be $298,000, which was recorded as contingent consideration. Through September 30, 2017, $60,000 of contingent consideration payments have been made.   On October 3, 2016, MAC acquired substantially all of the assets of MediGain. Since MediGain was in default of its obligations to Prudential prior to the acquisition, MAC purchased 100% of MediGain’s senior secured debt from Prudential.   The debt was collateralized by substantially all of MediGain’s assets, so immediately after purchasing the debt, MAC entered into a strict foreclosure agreement with MediGain transferring substantially all the assets (including accounts receivable, fixed assets, client relationships, and MediGain’s wholly-owned subsidiaries in India and Sri Lanka) to MAC in satisfaction of the outstanding obligations under the senior secured notes. The aggregate purchase price was $7 million which consisted of $2 million in cash paid at closing and $5 million, plus interest, which was paid during the third quarter of 2017.   MediGain, GCB, RMB and WFS are collectively referred to as the “2016 Acquisitions.” Revenue earned from the 2016 Acquisitions was approximately $4.1 million and $12.8 million during the three and nine months ended September 30, 2017, respectively.   Pro forma financial information (Unaudited)   The unaudited pro forma information below represents condensed consolidated results of operations as if the 2016 Acquisitions and the WMB Acquisition occurred on January 1, 2016. The pro forma information has been included for comparative purposes and is not indicative of results of operations of the Company would have had if the acquisitions occurred on the above date, nor is it necessarily indicative of future results.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Three Months Ended</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Nine Months Ended</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="14" style="text-align: center; line-height: 115%">($ in thousands, except per share data)</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; line-height: 115%">Total revenue</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 9%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">7,514</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 9%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">9,984</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 9%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">24,036</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 9%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">32,895</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Net loss attributable to common shareholders</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(1,581</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(4,316</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(6,584</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(13,830</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Net loss per common share</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.14</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.43</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.61</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(1.38</td> <td style="line-height: 115%">)</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"> </td> <td style="width: 24px; font: 11pt/115% Calibri, Helvetica, Sans-Serif">11.</td> <td style="font: 11pt/115% Calibri, Helvetica, Sans-Serif">STOCK-BASED COMPENSATION</td></tr> </table>   In April 2014, the Company adopted the Medical Transcription Billing, Corp. 2014 Equity Incentive Plan (the “2014 Plan”), reserving a total of 1,351,000 shares of common stock for grants to employees, officers, directors and consultants. During April 2017, the 2014 Plan was amended whereby an additional 1,500,000 shares of common stock and 100,000 shares of Preferred Stock were added to the plan for future issuance. The name of the 2014 Plan was changed to the Amended and Restated Equity Incentive Plan (the “Incentive Plan”). As of September 30, 2017, 1,238,734 shares of common stock and 67,000 shares of Preferred Stock are available for grant. Permissible awards include incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units (“RSUs”), performance stock and cash-settled awards and other stock-based awards in the discretion of the Compensation Committee of the Board of Directors including unrestricted stock grants.   The equity based RSUs contain a provision in which the units shall immediately vest and become converted into common shares at the rate of one common share per RSU, immediately after a change in control, as defined in the award agreement.   During the third quarter of 2017, a total of 200,000 RSUs were granted equally to the four outside members of the Board of directors and a total of 300,000 RSUs were granted equally to three executive officers. The RSUs vest over the next two years, at six month intervals.   The Company recognizes compensation expense on a straight-line basis over the total requisite service period for the entire award. For stock awards classified as equity, the market price of our common or Preferred Stock on the date of grant is used in recording the fair value of the award. For stock awards classified as a liability, the earned amount is marked to market based on the end of period common stock price. The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2017 and 2016:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Stock-based compensation included in the Condensed </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Three Months Ended September 30,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Nine Months Ended September 30,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr> <td style="vertical-align: top; line-height: 115%">Consolidated Statement of Operations:</td> <td style="vertical-align: bottom; text-align: center; line-height: 115%"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="vertical-align: bottom; text-align: center; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: center; line-height: 115%"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="vertical-align: bottom; text-align: center; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: center; line-height: 115%"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="vertical-align: bottom; text-align: center; line-height: 115%"> </td> <td style="vertical-align: bottom; text-align: center; line-height: 115%"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="vertical-align: bottom; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%; line-height: 115%">Direct operating costs</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">1,705</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">3,571</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">7,162</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">8,909</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">General and administrative</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">124,789</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">131,077</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">318,870</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">731,690</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Research and development</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(675</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3,767</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">7,822</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6,910</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Selling and marketing</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">5,378</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">18,086</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total stock-based compensation expense</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">125,819</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">143,793</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">333,854</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">765,595</td> <td style="line-height: 115%"> </td></tr> </table>   The following table summarizes the RSU and restricted stock transactions related to the common stock under the Incentive Plan for the nine months ended September 30, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 76%; line-height: 115%">Outstanding and unvested at January 1, 2017</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 21%; text-align: right; line-height: 115%">406,959</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">528,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Vested</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(327,159</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Forfeited</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(29,331</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Outstanding and unvested at September 30, 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">578,469</td> <td style="line-height: 115%"> </td></tr> </table>   Of the total outstanding and unvested at September 30, 2017, 548,334 RSUs and restricted stock awards are classified as equity and 30,135 RSUs are classified as a liability.   The liability for the cash-settled awards was approximately $17,000 and $31,000 at September 30, 2017 and December 31, 2016, respectively, and is included in accrued compensation in the condensed consolidated balance sheets.

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Three Months Ended</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Nine Months Ended</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="14" style="text-align: center; line-height: 115%">($ in thousands, except per share data)</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; line-height: 115%">Total revenue</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 9%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">7,514</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 9%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">9,984</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 9%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">24,036</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 9%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">32,895</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Net loss attributable to common shareholders</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(1,581</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(4,316</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(6,584</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(13,830</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Net loss per common share</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.14</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.43</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.61</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(1.38</td> <td style="line-height: 115%">)</td></tr> </table>

The following table presents the weighted-average shares outstanding for basic and diluted net loss per share for the three and nine months ended September 30, 2017 and 2016:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Three Months Ended</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">Nine Months Ended</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Basic and Diluted:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 44%; line-height: 115%">Net loss attributable to common shareholders</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(1,632,816</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(1,726,178</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(6,664,818</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(5,322,541</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Weighted average shares applicable to common shareholders used in computing basic and diluted loss per share</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">11,485,811</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">10,006,121</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">10,835,142</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">10,031,212</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Net loss attributable to common shareholders per share - Basic and Diluted</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.14</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.17</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.62</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(0.53</td> <td style="line-height: 115%">)</td></tr> </table>

Future minimum lease payments under non-cancelable operating leases for office space as of September 30, 2017 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Years Ending</td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">December 31</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%; line-height: 115%">2017 (three months)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 30%; text-align: right; line-height: 115%">68,994</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">304,357</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">2019</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">163,179</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">536,530</td> <td style="line-height: 115%"> </td></tr> </table>

24036000

32895000

7514000

9984000

-6584000

-13830000

-1581000

-4316000

282713

152712

5833706

2997211

618501

758785

13200

25203

4330901

3535673

202579

638905

5181459

246603

2666667

2000000

16626 16614 17000 17000

41666

52145

61437

79150

1236609

758357

2009911

848571

1905131

1017774

21256875

7377166

345530

510530

394072

131957

26673

30001

433186

371273

166184

137550

4033668

295

929

-376090

-440821

-17944230

-23325897

26038063

40985992

10793

12272

28323706

23947641

662000

0.22

0.23

0.24

1588937

1424732

7066831

16570475

295

10793

26038063

-17944230

-376090

-662000

929

12272

40985992

-23325897

-440821

-662000

275628

276000

294656

10792352

929299

12271390

-64731

907160

-1283151

3. BASIS OF PRESENTATION   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 8-03. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of items of a normal and recurring nature) necessary to present fairly the Company’s financial position as of September 30, 2017, the results of operations for the three and nine months ended September 30, 2017 and 2016 and cash flows for the nine months ended September 30, 2017 and 2016. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates.   The condensed consolidated balance sheet as of December 31, 2016 was derived from our audited consolidated financial statements. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2016, which are included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 31, 2017.   Recent Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently adopted and recently issued accounting pronouncements will not have a material impact on our consolidated financial position, results of operations and cash flows.   In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). The core principle of this amendment is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09, as amended by ASU 2015-14, ASU 2016-08, ASU 2016-10, ASU 2016-12 and ASU 2016-20, is effective for annual reporting periods beginning after December 15, 2017, and interim periods therein. These ASUs can be adopted either retrospectively to each prior reporting period presented or as a cumulative-effect adjustment as of the date of adoption. The Company plans to adopt Topic 606 using the modified retrospective method when it becomes effective for the Company in the first quarter of 2018. We have assigned internal resources to assist in the evaluation of the potential impacts of this amendment. Implementation efforts to date have included a review of revenue agreements and the performance obligations contained therein, and review of our commercial terms and practices across our revenue streams and a comparison of our current revenue recognition procedures to those required under Topic 606. While the Company is continuing to assess the effects of the amendment, management currently believes that the new guidance will not have a material impact on our revenue recognition policies, practices or systems. The Company is continuing to evaluate the effect that Topic 606 will have on its consolidated financial statements and related disclosures, and preliminary assessments are subject to change. We are in the process of finalizing the analysis of the requirements under Topic 606 and quantifying the effects if any, from the implementation which should be completed during the fourth quarter of 2017.   In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard will require organizations that lease assets — referred to as “lessees” — to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. Under the new guidance, a lessee will be required to recognize assets and liabilities for leases with lease terms of more than 12 months. Consistent with current GAAP, the recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. However, unlike current GAAP — which requires only capital leases to be recognized on the balance sheet — the new ASU will require both types of leases to be recognized on the balance sheet. The amendments in this ASU are effective for financial statements issued for annual periods beginning after December 15, 2018 with earlier adoption permitted. The Company is currently evaluating the impact of this new standard.   In January 2017, the FASB issued ASU No. 2017-01 Business Combinations (Topic 805): Clarifying the Definition of a Business. The ASU clarifies the definition of a business with the objective of adding guidance to assist companies and other reporting organizations with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or business. The amendments in this ASU provide a more robust framework to use in determining when a set of assets and activities is a business. The amendments provide more consistency in applying the guidance, reduce the costs of application, and make the definition of a business more operable. The ASU is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Upon adoption, the Company will apply the guidance in this ASU when evaluating whether acquired assets and activities constitute a business.   Also in January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment. The ASU modifies the accounting for goodwill impairment with the objective of simplifying the process of determining impairment levels. Specifically, the amendments in the ASU eliminate a step in the goodwill impairment test which requires companies to develop a hypothetical purchase price allocation when analyzing goodwill impairment. This eliminates the need for companies to estimate the fair value of individual existing assets and liabilities within a reporting unit. Instead, goodwill impairment will now be the amount by which a reporting unit’s total carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. All other aspects of the goodwill impairment test process have remained the same. The ASU is effective for annual periods beginning in the year 2020, with early adoption permitted for any impairment tests after January 1, 2017. The Company has elected to early adopt ASU 2017-04. There is currently no impact on the condensed consolidated financial statements as a result of this adoption.   In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation: Scope of Modification Accounting (Topic 718), which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. An entity will account for the effects of a modification unless the fair value of the modified award is the same as the original award, the vesting conditions of the modified award are the same as the original award and the classification of the modified award as an equity instrument or liability instrument is the same as the original award. The guidance is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. The update is to be adopted prospectively to an award modified on or after the adoption date. Early adoption is permitted. The Company is currently evaluating the effect of this update but does not believe it will have a material impact on its consolidated financial statements and related disclosures.

493264

1601110

827033

75804

38544

28032

13807

-32912

357671 205289

27145

-72360

672998

145038

17001

333854

765595

151423

-607978

-196882

-437557

160523

-107532

-211651

-1754255

90843

-1307637

-485728

499988

319870

-704988

-1744870

79603 153799

1908141

7626088

554002

7000000

6000000

7000000

6000000

335239

119406

846825

506603

546145

1400885

1290214

-75758

11317

-687498

-929067

3476880

2789382

7110495

8039562

30746 189725

678368

638905 202578

9513

32816

599950

321530

-0.62

-0.53

-0.14

-0.17

3200000

508000

1000000

2000000

5000000

4000000

2000000

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 0%"> </td> <td style="width: 24px; font: 11pt/115% Calibri, Helvetica, Sans-Serif">5.</td> <td style="font: 11pt/115% Calibri, Helvetica, Sans-Serif">GOODWILL AND INTANGIBLE ASSETS-NET</td></tr> </table>   Goodwill consists of the excess of the purchase price over the fair value of identifiable net assets of businesses acquired. The following is the summary of the changes to the carrying amount of goodwill for the nine months ended September 30, 2017 and the year ended December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2017</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2016</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; line-height: 115%">Beginning gross balance</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">12,178,868</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">8,971,994</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Acquisitions</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">85,075</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">3,206,874</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Ending gross balance</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">12,263,943</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">12,178,868</td> <td style="line-height: 115%"> </td></tr> </table>   Intangible assets include customer contracts and relationships and covenants not-to-compete acquired in connection with acquisitions, as well as software purchase and development costs and trademarks acquired. Intangible assets - net as of September 30, 2017 and December 31, 2016 consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; line-height: 115%">Contracts and relationships acquired</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">16,491,300</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">16,371,375</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Non-compete agreements</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,236,377</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,236,377</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Other intangible assets</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1,482,864</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1,289,339</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: 10pt; line-height: 115%">Total intangible assets</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">19,210,541</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">18,897,091</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Less: Accumulated amortization</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(16,213,330</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(13,063,385</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Intangible assets - net</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">2,997,211</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">5,833,706</td> <td style="line-height: 115%"> </td></tr> </table>   Amortization expense was approximately $3.2 million for both the nine months ended September 30, 2017 and 2016, and $508,000 and $1.0 million for the three months ended September 30, 2017 and 2016, respectively. The weighted-average amortization period is three years.   As of September 30, 2017, future amortization expense scheduled to be expensed is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Years ending</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">December 31</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%; line-height: 115%">2017 (three months)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 2%; line-height: 115%">$</td> <td style="width: 23%; text-align: right; line-height: 115%">493,264</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,601,110</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">827,033</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">2020</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">75,804</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">2,997,211</td> <td style="line-height: 115%"> </td></tr> </table>

As of September 30, 2017, future amortization expense scheduled to be expensed is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Years ending</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">December 31</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%; line-height: 115%">2017 (three months)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 2%; line-height: 115%">$</td> <td style="width: 23%; text-align: right; line-height: 115%">493,264</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,601,110</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">827,033</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">2020</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">75,804</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">2,997,211</td> <td style="line-height: 115%"> </td></tr> </table>

0.50

-0.61

-1.38

-0.14

-0.43

24000 60000

1000000

610000

1000000

1500000

100000

60195

255000

267

-267

24750

266663

1972065

1000

1971065

331676 212 331464 212375

13022267

609

13021658

609893

165000

114893

13484552

1270528

2000000

15. SUBSEQUENT EVENT   During October 2017, the Opus credit facility was replaced with a $5 million revolving line of credit from SVB. Interest on the SVB revolving line of credit is charged at the prime rate plus 1.75%. There is also a fee of one-half of 1% for the unused portion of the credit line. Available borrowings are subject to 200% of repeatable revenue as defined, reduced by an annualized attrition rate. The debt is secured by all of the Company’s domestic assets and 65% of the shares in its offshore facilities. Future acquisitions are subject to approval by SVB.   In connection with the SVB debt agreement, the Company paid approximately $90,000 of fees upfront and issued warrants for SVB to purchase 125,000 shares of its common stock, and committed to pay an annual anniversary fee of $50,000 a year. The warrants have a strike price equal to the highest volume weighted average price per share for any five consecutive trading days during the thirty consecutive trading-day period commencing on the fifteenth trading day immediately preceding the date of the loan agreement. They have a five-year exercise window, piggyback registration and net exercise rights, and will be valued once the strike price is determined. The SVB credit agreement contains various covenants and conditions governing the revolving line of credit.

25.00

2.30

3637131

3536940

664441

1118282

195912

8500

2017

205000

11530591

13000000

1300000

5600000

298698 313577 5000000 15000000

205000

120000

205000

85075

3206874

18897091

19210541

1236377

1289339

16491300

1236377

1482864

16371375

-13063385

-16213330

2000000

200000

0.65

463000

5000000

270000

3 to 6 year terms

0.0525

expiring through 2021.

690000

581000

131000

96000

141000

237000

202000

32000

47000

43000

68994

304357

163179

536530

12800000

13000

12000

4100000

4000

5000

1500

1600

13000

12000

1351000

1238734

67000

528000

200000

300000

548334

30135

31000

17000

333854

765595

7162

318870

7822

8909

731690

6910

18086

125819

143793

1705

124789

-675

3571

131077

3767

5378

578469

406959

-327159

29331

19000

7300000

1089099

669693

929549

1172508

678368

-151423

607978

-331676

79603

153799

0.0175

0.005

The preliminary purchase price allocation for WMB was performed by the Company and is summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%; line-height: 115%">Customer relationships</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 25%; text-align: right; line-height: 115%">120,000</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Goodwill</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">85,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">205,000</td> <td style="line-height: 115%"> </td></tr> </table>

Goodwill consists of the excess of the purchase price over the fair value of identifiable net assets of businesses acquired. The following is the summary of the changes to the carrying amount of goodwill for the nine months ended September 30, 2017 and the year ended December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2017</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2016</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; line-height: 115%">Beginning gross balance</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">12,178,868</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">8,971,994</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Acquisitions</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">85,075</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">3,206,874</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Ending gross balance</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">12,263,943</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">12,178,868</td> <td style="line-height: 115%"> </td></tr> </table>

Intangible assets include customer contracts and relationships and covenants not-to-compete acquired in connection with acquisitions, as well as software purchase and development costs and trademarks acquired. Intangible assets - net as of September 30, 2017 and December 31, 2016 consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">September 30, 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2016</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; line-height: 115%">Contracts and relationships acquired</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">16,491,300</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 22%; text-align: right; line-height: 115%">16,371,375</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Non-compete agreements</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,236,377</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,236,377</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Other intangible assets</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1,482,864</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1,289,339</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: 10pt; line-height: 115%">Total intangible assets</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">19,210,541</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">18,897,091</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Less: Accumulated amortization</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(16,213,330</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(13,063,385</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Intangible assets - net</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">2,997,211</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">5,833,706</td> <td style="line-height: 115%"> </td></tr> </table>

26296 463000 2.00

165000

175000

25.00

2.75

0.65 90000

125000

50000

0.27

5833706

2997211

12178868

12263943

8971994

1.00

7000000

2000000

5000000 0001582982 2.00 913000 No tax effect has been recorded as the Company recorded a valuation allowance against the tax benefit from its foreign currency translation adjustments.

EX-101.SCH 7 mtbc-20170930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited Sep 30, 2017) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited Sep 30, 2017) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statement of Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Goodwill and Intangible Assets-Net link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Shareholders' Equity Transactions link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Related Parties link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Restructuring Charges link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Goodwill and Intangible Assets-Net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Net Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Organization and Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Liquidity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Acquisitions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Acquisitions - Business Acquisition, Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Goodwill and Intangible Assets-Net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Goodwill and Intangible Assets-Net - Schedule of Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Goodwill and Intangible Assets-Net - Schedule of Finite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Goodwill and Intangible Assets-Net - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Net Loss Per Common Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Net Loss Per Common Share - Schedule of Losses Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Shareholders' Equity Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Related Parties (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Stock-Based Compensation - Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Restructuring Charges (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Fair Value of Financial Instruments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Subsequent Event (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 mtbc-20170930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 mtbc-20170930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 mtbc-20170930_lab.xml XBRL LABEL FILE Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Loss [Member] Treasury (Common) Stock [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Asset Purchase Agreement [Member] Business Acquisition [Axis] Renaissance Medical Billing, LLC [Member] Gulf Coast Billing Inc [Member] 2016 Acquisitions [Member] Long-term Debt, Type [Axis] Opus Bank Loan [Member] Scenario [Axis] Total [Member] Award Type [Axis] Term Loan [Member] Credit Facility [Axis] Revolving Credit Facility [Member] Vehicle Financing Notes [Member] Title of Individual [Axis] Chief Executive Officer [Member] Physician [Member] Related Party [Axis] Kashmir Air, Inc [Member] Plan Name [Axis] 2014 Equity Incentive Plan [Member] Employees Officers Directors and Consultants [Member] Restricted Stock Units (RSUs) [Member] Income Statement Location [Axis] Direct Operating Costs [Member] General and Administrative [Member] Research and Development [Member] Selling and Marketing [Member] Fair Value, Hierarchy [Axis] Fair Value, Input, Level 3 [Member] WFS Services, Inc. [Member] Legal Entity [Axis] MediGain [Member] Finite-Lived Intangible Assets by Major Class [Axis] Non-Compete Agreements [Member] Other Intangible Assets [Member] Fair Value, Inputs, Level 2 [Member] Opus Debt [Member] MTBC [Member] Class of Stock [Axis] 11% Series A Cumulative Redeemable Preferred Stock [Member] Lender Name [Axis] Opus Bank [Member] Washington Medical Billing, LLC [Member] Business Combination, Separately Recognized Transactions [Axis] First Year [Member] Concentration Risk Benchmark [Axis] Revenue Collected from WMB Accounts [Member] Second Year [Member] Third Year [Member] Amended and Restated Equity Incentive Plan [Member] Series A Preferred Stock [Member] WMB [Member] Contracts and Relationships Acquired [Member] Two Public Preferred Stock Offerings [Member] Board of Directors [Member] Three Executive Officers [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Opus Credit Facility [Member] Variable Rate [Axis] Prime Rate [Member] SVB Credit Facility Agreement [Member] Report Date [Axis] October 2017 [Member] SVB Debt Agreement [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash Accounts receivable - net of allowance for doubtful accounts of $268,000 and $156,000 at September 30, 2017 and December 31, 2016, respectively Current assets - related party Prepaid expenses and other current assets Total current assets Property and equipment - net Intangible assets - net Goodwill Other assets TOTAL ASSETS LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable Accrued compensation Accrued expenses Deferred rent (current portion) Deferred revenue (current portion) Accrued liability to related party Borrowings under line of credit Current portion of long-term debt Notes payable - other (current portion) Contingent consideration (current portion) Dividend payable Total current liabilities Long - term debt, net of discount and debt issuance costs Notes payable - other Deferred rent Deferred revenue Contingent consideration Deferred tax liability Total liabilities COMMITMENTS AND CONTINGENCIES (Note 8) SHAREHOLDERS' EQUITY: Preferred stock, par value $0.001 per share - authorized 2,000,000 shares; issued and outstanding 929,299 and 294,656 shares at September 30, 2017 and December 31, 2016, respectively Common stock, $0.001 par value - authorized 19,000,000 shares; issued 12,271,390 and 10,792,352 shares at September 30, 2017 and December 31, 2016, respectively; outstanding, 11,530,591 and 10,051,553 shares at September 30, 2017 and December 31, 2016, respectively Additional paid-in capital Accumulated deficit Accumulated other comprehensive loss Less: 740,799 common shares held in treasury, at cost at September 30, 2017 and December 31, 2016 Total shareholders' equity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Allowance for doubtful accounts receivable Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares, issued Common stock, shares, outstanding Treasury stock, shares Income Statement [Abstract] NET REVENUE OPERATING EXPENSES: Direct operating costs Selling and marketing General and administrative Research and development Change in contingent consideration Depreciation and amortization Restructuring charges Total operating expenses OPERATING LOSS OTHER: Interest income Interest expense Other income (expense) - net LOSS BEFORE INCOME TAXES Income tax provision NET LOSS Preferred stock dividend NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS Loss per common share: Basic and diluted loss per share Weighted-average basic and diluted shares outstanding Statement of Comprehensive Income [Abstract] NET LOSS OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX Foreign currency translation adjustment (a) COMPREHENSIVE LOSS Statement [Table] Statement [Line Items] Balance Balance, shares Net loss Foreign currency translation adjustment Issuance of stock under the Amended and Restated Equity Incentive Plan Issuance of stock under the Amended and Restated Equity Incentive Plan, shares Stock-based compensation, net of cash settlements Issuance of common stock, net of fees and expenses Issuance of common stock, net of fees and expenses, shares Issuance of common stock held as contingent consideration Issuance of common stock held as contingent consideration, shares Issuance of preferred stock, net of fees and expenses Issuance of preferred stock, net of fees and expenses, shares Preferred stock dividends Balance Balance, shares Statement of Cash Flows [Abstract] OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Deferred rent Deferred revenue Provision for doubtful accounts EX-101.PRE 11 mtbc-20170930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Nov. 01, 2017
Document And Entity Information
Entity Registrant Name	MEDICAL TRANSCRIPTION BILLING, CORP
Entity Central Index Key	0001582982
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		11,530,591
Trading Symbol	MTBC
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited Sep 30, 2017) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash	$ 2,789,382	$ 3,476,880
Accounts receivable - net of allowance for doubtful accounts of $268,000 and $156,000 at September 30, 2017 and December 31, 2016, respectively	3,535,673	4,330,901
Current assets - related party	25,203	13,200
Prepaid expenses and other current assets	758,785	618,501
Total current assets	7,109,043	8,439,482
Property and equipment - net	1,424,732	1,588,937
Intangible assets - net	2,997,211	5,833,706
Goodwill	12,263,943	12,178,868
Other assets	152,712	282,713
TOTAL ASSETS	23,947,641	28,323,706
CURRENT LIABILITIES:
Accounts payable	1,017,774	1,905,131
Accrued compensation	848,571	2,009,911
Accrued expenses	758,357	1,236,609
Deferred rent (current portion)	79,150	61,437
Deferred revenue (current portion)	52,145	41,666
Accrued liability to related party	16,614	16,626
Borrowings under line of credit	2,000,000	2,000,000
Current portion of long-term debt		2,666,667
Notes payable - other (current portion)	246,603	5,181,459
Contingent consideration (current portion)	537,736	535,477
Dividend payable	638,905	202,579
Total current liabilities	6,195,855	15,857,562
Long - term debt, net of discount and debt issuance costs		4,033,668
Notes payable - other	137,550	166,184
Deferred rent	371,273	433,186
Deferred revenue	30,001	26,673
Contingent consideration	131,957	394,072
Deferred tax liability	510,530	345,530
Total liabilities	7,377,166	21,256,875
COMMITMENTS AND CONTINGENCIES (Note 8)
SHAREHOLDERS' EQUITY:
Preferred stock, par value $0.001 per share - authorized 2,000,000 shares; issued and outstanding 929,299 and 294,656 shares at September 30, 2017 and December 31, 2016, respectively	929	295
Common stock, $0.001 par value - authorized 19,000,000 shares; issued 12,271,390 and 10,792,352 shares at September 30, 2017 and December 31, 2016, respectively; outstanding, 11,530,591 and 10,051,553 shares at September 30, 2017 and December 31, 2016, respectively	12,272	10,793
Additional paid-in capital	40,985,992	26,038,063
Accumulated deficit	(23,325,897)	(17,944,230)
Accumulated other comprehensive loss	(440,821)	(376,090)
Less: 740,799 common shares held in treasury, at cost at September 30, 2017 and December 31, 2016	(662,000)	(662,000)
Total shareholders' equity	16,570,475	7,066,831
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 23,947,641	$ 28,323,706

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited Sep 30, 2017) (Parenthetical) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 268,000	$ 156,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	929,299	294,656
Preferred stock, shares outstanding	929,299	294,656
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	19,000,000	19,000,000
Common stock, shares, issued	12,271,390	10,792,352
Common stock, shares, outstanding	11,530,591	10,051,553
Treasury stock, shares	740,799	740,799

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
NET REVENUE	$ 7,513,592	$ 5,341,002	$ 23,518,416	$ 15,663,687
OPERATING EXPENSES:
Direct operating costs	4,171,932	2,670,385	13,592,492	7,292,415
Selling and marketing	228,991	274,796	853,460	838,721
General and administrative	2,474,139	2,569,399	8,232,613	8,173,272
Research and development	249,045	174,876	843,294	575,059
Change in contingent consideration		(196,882)	151,423	(607,978)
Depreciation and amortization	664,441	1,118,282	3,637,131	3,536,940
Restructuring charges			275,628
Total operating expenses	7,788,548	6,610,856	27,586,041	19,808,429
OPERATING LOSS	(274,956)	(1,269,854)	(4,067,625)	(4,144,742)
OTHER:
Interest income	5,446	10,918	13,598	25,310
Interest expense	(678,103)	(176,527)	(1,242,672)	(486,481)
Other income (expense) - net	32,494	(13,933)	107,364	(40,447)
LOSS BEFORE INCOME TAXES	(915,119)	(1,449,396)	(5,189,335)	(4,646,360)
Income tax provision	65,000	45,309	192,332	126,236
NET LOSS	(980,119)	(1,494,705)	(5,381,667)	(4,772,596)
Preferred stock dividend	652,697	231,473	1,283,151	549,945
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (1,632,816)	$ (1,726,178)	$ (6,664,818)	$ (5,322,541)
Loss per common share:
Basic and diluted loss per share	$ (0.14)	$ (0.17)	$ (0.62)	$ (0.53)
Weighted-average basic and diluted shares outstanding	11,485,811	10,006,121	10,835,142	10,031,212

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)

3 Months Ended

9 Months Ended

Sep. 30, 2017

Sep. 30, 2016

Sep. 30, 2017

Sep. 30, 2016

Statement of Comprehensive Income [Abstract]

NET LOSS

$ (980,119)

$ (1,494,705)

$ (5,381,667)

$ (4,772,596)

OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX

Foreign currency translation adjustment (a)

^[1]

(33,880)

1,489

(64,731)

12,305

COMPREHENSIVE LOSS

$ (1,013,999)

$ (1,493,216)

$ (5,446,398)

$ (4,760,291)

[1]	No tax effect has been recorded as the Company recorded a valuation allowance against the tax benefit from its foreign currency translation adjustments.

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Shareholders' Equity (Unaudited) - 9 months ended Sep. 30, 2017 - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Treasury (Common) Stock [Member]	Total
Balance at Dec. 31, 2016	$ 295	$ 10,793	$ 26,038,063	$ (17,944,230)	$ (376,090)	$ (662,000)	$ 7,066,831
Balance, shares at Dec. 31, 2016	294,656	10,792,352
Net loss				(5,381,667)			(5,381,667)
Foreign currency translation adjustment					(64,731)		(64,731)
Issuance of stock under the Amended and Restated Equity Incentive Plan	$ 25	$ 267	(267)				25
Issuance of stock under the Amended and Restated Equity Incentive Plan, shares	24,750	266,663
Stock-based compensation, net of cash settlements			907,160				907,160
Issuance of common stock, net of fees and expenses		$ 1,000	1,971,065				1,972,065
Issuance of common stock, net of fees and expenses, shares		1,000,000
Issuance of common stock held as contingent consideration		$ 212	331,464				331,676
Issuance of common stock held as contingent consideration, shares		212,375
Issuance of preferred stock, net of fees and expenses	$ 609		13,021,658				13,022,267
Issuance of preferred stock, net of fees and expenses, shares	609,893
Preferred stock dividends			(1,283,151)				(1,283,151)
Balance at Sep. 30, 2017	$ 929	$ 12,272	$ 40,985,992	$ (23,325,897)	$ (440,821)	$ (662,000)	$ 16,570,475
Balance, shares at Sep. 30, 2017	929,299	12,271,390

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
OPERATING ACTIVITIES:
Net loss	$ (5,381,667)	$ (4,772,596)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,637,131	3,536,940
Deferred rent	(38,544)	(28,032)
Deferred revenue	13,807	(32,912)
Provision for doubtful accounts	357,671	205,289
Provision for deferred income taxes	165,000	114,893
Foreign exchange (gain) loss	(27,145)	72,360
Interest accretion and write-off of deferred financing costs	672,998	145,038
Non-cash restructuring charges	17,001
Stock-based compensation expense	333,854	765,595
Change in contingent consideration	151,423	(607,978)
Acquisition settlements		(26,296)
Changes in operating assets and liabilities:
Accounts receivable	437,557	(160,523)
Other assets	107,532	211,651
Accounts payable and other liabilities	(1,754,255)	90,843
Net cash used in operating activities	(1,307,637)	(485,728)
INVESTING ACTIVITIES:
Capital expenditures	(499,988)	(319,870)
Cash paid for acquisitions	(205,000)	(1,425,000)
Net cash used in investing activities	(704,988)	(1,744,870)
FINANCING ACTIVITIES:
Contingent consideration payments	(79,603)	(153,799)
Settlement of tax withholding obligations on stock issued to employees	(195,912)	(8,500)
Proceeds from issuance of common stock, net of placement costs	2,000,000
Proceeds from issuance of preferred stock, net of placement costs	13,484,552	1,270,528
Proceeds from long term debt, net of costs		1,908,141
Repayments of debt obligations	(7,626,088)	(554,002)
Repayment of Prudential obligation	(5,000,000)
Proceeds from line of credit	7,000,000	6,000,000
Repayments of line of credit	(7,000,000)	(6,000,000)
Payment of registration statement and bank costs	(335,239)	(119,406)
Preferred stock dividends paid	(846,825)	(506,603)
Purchase of common shares		(546,145)
Net cash provided by financing activities	1,400,885	1,290,214
EFFECT OF EXCHANGE RATE CHANGES ON CASH	(75,758)	11,317
NET DECREASE IN CASH	(687,498)	(929,067)
CASH - Beginning of the period	3,476,880	8,039,562
CASH - End of period	2,789,382	7,110,495
SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES:
Vehicle financing obtained	30,746	189,725
Contingent consideration resulting from acquisitions		678,368
Dividends declared, not paid	638,905	202,578
Purchase of prepaid insurance through assumption of note	298,698	313,577
SUPPLEMENTAL INFORMATION - Cash paid during the period for:
Income taxes	9,513	32,816
Interest	$ 599,950	$ 321,530

XML 19 R8.htm IDEA: XBRL DOCUMENT

Organization and Business

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Business

1. Organization and Business

XML 20 R9.htm IDEA: XBRL DOCUMENT

Liquidity

9 Months Ended

Sep. 30, 2017

Liquidity [Abstract]

Liquidity

2. Liquidity

XML 21 R10.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

3. BASIS OF PRESENTATION

XML 22 R11.htm IDEA: XBRL DOCUMENT

Acquisitions

9 Months Ended

Sep. 30, 2017

Business Combinations [Abstract]

Acquisitions

4. ACQUISITIONS

2017 Acquisition

The preliminary purchase price allocation for WMB was performed by the Company and is summarized as follows:

Customer relationships	$	120,000
Goodwill		85,000
	$	205,000

The weighted-average amortization period of the acquired intangible assets is three years.

Revenue earned from the WMB acquisition was approximately $165,000 during the quarter ended September 30, 2017.

2016 Acquisitions

Pro forma financial information (Unaudited)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2017			2016			2017			2016
	($ in thousands, except per share data)
Total revenue	$	7,514		$	9,984		$	24,036		$	32,895
Net loss attributable to common shareholders	$	(1,581	)	$	(4,316	)	$	(6,584	)	$	(13,830	)
Net loss per common share	$	(0.14	)	$	(0.43	)	$	(0.61	)	$	(1.38	)

XML 23 R12.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets-Net

9 Months Ended

Sep. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets-Net

GOODWILL AND INTANGIBLE ASSETS-NET

	September 30, 2017		December 31, 2016
Beginning gross balance	$	12,178,868	$	8,971,994
Acquisitions		85,075		3,206,874
Ending gross balance	$	12,263,943	$	12,178,868

	September 30, 2017			December 31, 2016
Contracts and relationships acquired	$	16,491,300		$	16,371,375
Non-compete agreements		1,236,377			1,236,377
Other intangible assets		1,482,864			1,289,339
Total intangible assets		19,210,541			18,897,091
Less: Accumulated amortization		(16,213,330	)		(13,063,385	)
Intangible assets - net	$	2,997,211		$	5,833,706

As of September 30, 2017, future amortization expense scheduled to be expensed is as follows:

Years ending
December 31
2017 (three months)	$	493,264
2018		1,601,110
2019		827,033
2020		75,804
Total	$	2,997,211

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share

9 Months Ended

Sep. 30, 2017

Loss per common share:

Net Loss Per Common Share

NET LOss per COMMON share

The following table presents the weighted-average shares outstanding for basic and diluted net loss per share for the three and nine months ended September 30, 2017 and 2016:

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
		2017			2016			2017			2016
Basic and Diluted:
Net loss attributable to common shareholders	$	(1,632,816	)	$	(1,726,178	)	$	(6,664,818	)	$	(5,322,541	)
Weighted average shares applicable to common shareholders used in computing basic and diluted loss per share		11,485,811			10,006,121			10,835,142			10,031,212
Net loss attributable to common shareholders per share - Basic and Diluted	$	(0.14	)	$	(0.17	)	$	(0.62	)	$	(0.53	)

XML 25 R14.htm IDEA: XBRL DOCUMENT

Debt

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Debt

Debt

Insurance Financing — The Company finances certain insurance purchases over the term of the policy life. The interest rate charged is 5.25%.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Leases — The Company leases certain office space and other facilities under operating leases expiring through 2021. Certain of these leases contain renewal options.

Future minimum lease payments under non-cancelable operating leases for office space as of September 30, 2017 are as follows:

Years Ending
December 31	Total
2017 (three months)	$	68,994
2018		304,357
2019		163,179
Total	$	536,530

XML 27 R16.htm IDEA: XBRL DOCUMENT

Shareholders' Equity Transactions

9 Months Ended

Sep. 30, 2017

Equity [Abstract]

Shareholders' Equity Transactions

SHAREHOLDERS’ EQUITY TRANSACTIONS

XML 28 R17.htm IDEA: XBRL DOCUMENT

Related Parties

9 Months Ended

Sep. 30, 2017

Related Parties

10.

Related PARTIES

XML 29 R18.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

11.

STOCK-BASED COMPENSATION

Stock-based compensation included in the Condensed	Three Months Ended September 30,					Nine Months Ended September 30,
Consolidated Statement of Operations:	2017			2016		2017		2016
Direct operating costs	$	1,705		$	3,571	$	7,162	$	8,909
General and administrative		124,789			131,077		318,870		731,690
Research and development		(675	)		3,767		7,822		6,910
Selling and marketing		-			5,378		-		18,086
Total stock-based compensation expense	$	125,819		$	143,793	$	333,854	$	765,595

The following table summarizes the RSU and restricted stock transactions related to the common stock under the Incentive Plan for the nine months ended September 30, 2017:

Outstanding and unvested at January 1, 2017	406,959
Granted	528,000
Vested	(327,159	)
Forfeited	(29,331	)
Outstanding and unvested at September 30, 2017	578,469

Of the total outstanding and unvested at September 30, 2017, 548,334 RSUs and restricted stock awards are classified as equity and 30,135 RSUs are classified as a liability.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2017

Income Tax Disclosure [Abstract]

Income Taxes

12.

INCOME TAXES

The deferred income tax provision for the nine months ended September 30, 2017 and 2016 primarily relates to the amortization of goodwill.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Restructuring Charges

9 Months Ended

Sep. 30, 2017

Restructuring and Related Activities [Abstract]

Restructuring Charges

13.

RESTRUCTURING CHARGES

XML 32 R21.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

14.

FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value measurements-Level 2

Contingent Consideration

The following table provides a reconciliation of the beginning and ending balances for the contingent consideration measured at fair value using significant unobservable inputs (Level 3):

	Fair Value Measurement at Reporting Date Using Significant Unobservable Inputs, Level 3
	Nine Months Ended September 30,
	2017			2016
Balance - January 1,	$	929,549		$	1,172,508
Acquisitions		-			678,368
Change in fair value		151,423			(607,978	)
Settlement in the form of shares issued		(331,676	)		-
Payments		(79,603	)		(153,799	)
Balance - September 30,	$	669,693		$	1,089,099

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

Subsequent Event

9 Months Ended

Sep. 30, 2017

Subsequent Events [Abstract]

Subsequent Event

15. SUBSEQUENT EVENT

XML 34 R23.htm IDEA: XBRL DOCUMENT

Acquisitions (Tables)

9 Months Ended

Sep. 30, 2017

Business Combinations [Abstract]

Schedule of Business Acquisitions, by Acquisition

The preliminary purchase price allocation for WMB was performed by the Company and is summarized as follows:

Customer relationships	$	120,000
Goodwill		85,000
	$	205,000

Business Acquisition, Pro Forma Information

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2017			2016			2017			2016
	($ in thousands, except per share data)
Total revenue	$	7,514		$	9,984		$	24,036		$	32,895
Net loss attributable to common shareholders	$	(1,581	)	$	(4,316	)	$	(6,584	)	$	(13,830	)
Net loss per common share	$	(0.14	)	$	(0.43	)	$	(0.61	)	$	(1.38	)

XML 35 R24.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets-Net (Tables)

9 Months Ended

Sep. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill

	September 30, 2017		December 31, 2016
Beginning gross balance	$	12,178,868	$	8,971,994
Acquisitions		85,075		3,206,874
Ending gross balance	$	12,263,943	$	12,178,868

Schedule of Finite-Lived Intangible Assets

	September 30, 2017			December 31, 2016
Contracts and relationships acquired	$	16,491,300		$	16,371,375
Non-compete agreements		1,236,377			1,236,377
Other intangible assets		1,482,864			1,289,339
Total intangible assets		19,210,541			18,897,091
Less: Accumulated amortization		(16,213,330	)		(13,063,385	)
Intangible assets - net	$	2,997,211		$	5,833,706

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

As of September 30, 2017, future amortization expense scheduled to be expensed is as follows:

Years ending
December 31
2017 (three months)	$	493,264
2018		1,601,110
2019		827,033
2020		75,804
Total	$	2,997,211

XML 36 R25.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share (Tables)

9 Months Ended

Sep. 30, 2017

Loss per common share:

Schedule of Losses Per Share, Basic and Diluted

The following table presents the weighted-average shares outstanding for basic and diluted net loss per share for the three and nine months ended September 30, 2017 and 2016:

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
		2017			2016			2017			2016
Basic and Diluted:
Net loss attributable to common shareholders	$	(1,632,816	)	$	(1,726,178	)	$	(6,664,818	)	$	(5,322,541	)
Weighted average shares applicable to common shareholders used in computing basic and diluted loss per share		11,485,811			10,006,121			10,835,142			10,031,212
Net loss attributable to common shareholders per share - Basic and Diluted	$	(0.14	)	$	(0.17	)	$	(0.62	)	$	(0.53	)

XML 37 R26.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases

Future minimum lease payments under non-cancelable operating leases for office space as of September 30, 2017 are as follows:

Years Ending
December 31	Total
2017 (three months)	$	68,994
2018		304,357
2019		163,179
Total	$	536,530

XML 38 R27.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2017 and 2016:

Stock-based compensation included in the Condensed	Three Months Ended September 30,					Nine Months Ended September 30,
Consolidated Statement of Operations:	2017			2016		2017		2016
Direct operating costs	$	1,705		$	3,571	$	7,162	$	8,909
General and administrative		124,789			131,077		318,870		731,690
Research and development		(675	)		3,767		7,822		6,910
Selling and marketing		-			5,378		-		18,086
Total stock-based compensation expense	$	125,819		$	143,793	$	333,854	$	765,595

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award

The following table summarizes the RSU and restricted stock transactions related to the common stock under the Incentive Plan for the nine months ended September 30, 2017:

Outstanding and unvested at January 1, 2017	406,959
Granted	528,000
Vested	(327,159	)
Forfeited	(29,331	)
Outstanding and unvested at September 30, 2017	578,469

XML 39 R28.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The following table provides a reconciliation of the beginning and ending balances for the contingent consideration measured at fair value using significant unobservable inputs (Level 3):

	Fair Value Measurement at Reporting Date Using Significant Unobservable Inputs, Level 3
	Nine Months Ended September 30,
	2017			2016
Balance - January 1,	$	929,549		$	1,172,508
Acquisitions		-			678,368
Change in fair value		151,423			(607,978	)
Settlement in the form of shares issued		(331,676	)		-
Payments		(79,603	)		(153,799	)
Balance - September 30,	$	669,693		$	1,089,099

XML 40 R29.htm IDEA: XBRL DOCUMENT

Organization and Business (Details Narrative)	Sep. 30, 2017
Chief Executive Officer [Member]
Equity method investment, ownership percentage in majority-owned subsidiary based in Pakistan	0.01%
MTBC [Member]
Equity method investment, ownership percentage in majority-owned subsidiary based in Pakistan	99.90%

XML 41 R30.htm IDEA: XBRL DOCUMENT

Liquidity (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
Liquidity (Details Narrative) - USD ($)	May 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Cash		$ 2,789,382	$ 7,110,495	$ 2,789,382	$ 7,110,495	$ 3,476,880	$ 8,039,562
Working capital surplus		913,000		913,000
Net loss before taxes		915,119	1,449,396	5,189,335	4,646,360
Depreciation and amortization expenses		664,441	$ 1,118,282	3,637,131	3,536,940
Non cash financing cost		463,000
Proceeds from a series of equity financings				15,000,000
Net proceeds from issuance of common stock				2,000,000
Opus Credit Facility [Member]
Line of credit		2,000,000		2,000,000
SVB Credit Facility Agreement [Member] \| October 2017 [Member]
Line of credit		4,000,000		4,000,000
Line of credit facility Maximum borrowing capacity		$ 5,000,000		$ 5,000,000
Revolving line of credit secured on repeatable revenue percentage		200.00%		200.00%
11% Series A Cumulative Redeemable Preferred Stock [Member]
Number of stock shares issued during the period				610,000
Shares issued price per share		$ 25.00		$ 25.00
Net proceeds from issuance of preferred stock				$ 13,000,000
Common Stock [Member]
Number of stock shares issued during the period	1,000,000			1,000,000
Shares issued price per share	$ 2.30
Net proceeds from issuance of common stock	$ 2,000,000

XML 42 R31.htm IDEA: XBRL DOCUMENT

Acquisitions (Details Narrative) - USD ($)					3 Months Ended	9 Months Ended
Acquisitions (Details Narrative) - USD ($)	Jul. 01, 2017	Oct. 03, 2016	Jul. 01, 2016	May 02, 2016	Sep. 30, 2017	Sep. 30, 2017	Feb. 15, 2016
Payments to acquire business						$ 205,000
Weighted-average amortization period of acquired intangible assets						3 years
Revenue earned from the WMB acquisition						$ 165,000
MediGain [Member]
Purchase of percentage of senior secured debt		100.00%
Purchase price for acquisition		$ 7,000,000
Purchase price paid at closing		$ 2,000,000
Purchase price paid during 2017					$ 5,000,000
Washington Medical Billing, LLC [Member] \| First Year [Member] \| Revenue Collected from WMB Accounts [Member]
Installment payments percentage	22.00%
Washington Medical Billing, LLC [Member] \| Second Year [Member] \| Revenue Collected from WMB Accounts [Member]
Installment payments percentage	23.00%
Washington Medical Billing, LLC [Member] \| Third Year [Member] \| Revenue Collected from WMB Accounts [Member]
Installment payments percentage	24.00%
Gulf Coast Billing Inc [Member]
Business combination, recognized identifiable assets acquired and liabilities assumed, liabilities, total							$ 1,480,000
Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents paid							1,250,000
Business combination, contingent consideration							$ 230,000
2016 Acquisitions [Member]
Revenues					$ 4,100,000	$ 12,800,000
Asset Purchase Agreement [Member] \| Washington Medical Billing, LLC [Member]
Non-refundable initial payment amount	$ 205,000
Asset Purchase Agreement [Member] \| Renaissance Medical Billing, LLC [Member]
Business combination, recognized identifiable assets acquired and liabilities assumed, liabilities, total				$ 325,000
Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents paid				175,000
Business combination, contingent consideration				150,000
Initial cash consideration				$ 175,000
Future payment as a percentage of revenue				27.00%
Contingent consideration paid since acquisition through September 30, 2017				$ 24,000
Asset Purchase Agreement [Member] \| WFS Services, Inc. [Member]
Business combination, recognized identifiable assets acquired and liabilities assumed, liabilities, total			$ 298,000
Business combination, contingent consideration			298,000
Contingent consideration paid since acquisition through September 30, 2017			60,000
Required monthly payments			$ 5,000
Future payment as a percentage of EBITDA			50.00%

XML 43 R32.htm IDEA: XBRL DOCUMENT

Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Goodwill	$ 12,263,943	$ 12,178,868
WMB [Member]
Customer relationships	120,000
Goodwill	85,000
Total	$ 205,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

Acquisitions - Business Acquisition, Pro Forma Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Business Combinations [Abstract]
Total revenue	$ 7,514	$ 9,984	$ 24,036	$ 32,895
Net loss attributable to common shareholders	$ (1,581)	$ (4,316)	$ (6,584)	$ (13,830)
Net loss per common share	$ (0.14)	$ (0.43)	$ (0.61)	$ (1.38)

XML 45 R34.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets-Net (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expenses	$ 508,000	$ 1,000,000	$ 3,200,000	$ 3,200,000
Weighted-average amortization period			3 years

XML 46 R35.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets-Net - Schedule of Intangible Assets and Goodwill (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning gross balance	$ 12,178,868	$ 8,971,994
Acquisitions	85,075	3,206,874
Ending gross balance	$ 12,263,943	$ 12,178,868

XML 47 R36.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets-Net - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Total intangible assets	$ 19,210,541	$ 18,897,091
Less: Accumulated amortization	(16,213,330)	(13,063,385)
Intangible assets- net	2,997,211	5,833,706
Contracts and Relationships Acquired [Member]
Total intangible assets	16,491,300	16,371,375
Non-Compete Agreements [Member]
Total intangible assets	1,236,377	1,236,377
Other Intangible Assets [Member]
Total intangible assets	$ 1,482,864	$ 1,289,339

XML 48 R37.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets-Net - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
2017 (three months)	$ 493,264
2018	1,601,110
2019	827,033
2020	75,804
Total	$ 2,997,211	$ 5,833,706

XML 49 R38.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share (Details Narrative) - shares	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Number of warrant shares granted	2,000,000
Opus Bank [Member]
Number of warrant shares granted		200,000	200,000

XML 50 R39.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share - Schedule of Losses Per Share, Basic and Diluted (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Loss per common share:
Net loss attributable to common shareholders	$ (1,632,816)	$ (1,726,178)	$ (6,664,818)	$ (5,322,541)
Weighted average shares applicable to common shareholders used in computing basic and diluted loss per share	11,485,811	10,006,121	10,835,142	10,031,212
Net loss attributable to common shareholders per share - Basic and Diluted	$ (0.14)	$ (0.17)	$ (0.62)	$ (0.53)

XML 51 R40.htm IDEA: XBRL DOCUMENT

Debt (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
Debt (Details Narrative) - USD ($)	Sep. 30, 2017	Sep. 30, 2017	Sep. 02, 2015
Deferred financing costs	$ 463,000	$ 463,000
Payments for deferred purchase Price	5,000,000
Accrued interest	$ 270,000	$ 270,000
Insurance financing interest rate	5.25%	5.25%
Opus Bank Loan [Member]
Percentage of shares secured for debt		65.00%
Opus Bank Loan [Member] \| Revolving Credit Facility [Member]
Credit facility, maximum borrowing capacity			$ 2,000,000
Opus Bank Loan [Member] \| Term Loan [Member]
Credit facility, maximum borrowing capacity			8,000,000
Vehicle Financing Notes [Member]
Debt instrument term description		3 to 6 year terms
Total [Member] \| Opus Bank Loan [Member]
Credit facility, maximum borrowing capacity			$ 10,000,000

XML 52 R41.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Operating leases expire year			expiring through 2021.
Operating leases, rent expense	$ 237,000	$ 202,000	$ 690,000	$ 581,000

XML 53 R42.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details)	Sep. 30, 2017 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2017 (three months)	$ 68,994
2018	304,357
2019	163,179
Total	$ 536,530

XML 54 R43.htm IDEA: XBRL DOCUMENT

Shareholders' Equity Transactions (Details Narrative) - Preferred Stock [Member] - USD ($)	1 Months Ended		9 Months Ended
	Sep. 30, 2017	Aug. 31, 2017	Sep. 30, 2017
Number of stock shares issued during the period		60,195
Shares issued price per share	$ 25.00	$ 25.00	$ 25.00
Net proceeds from issuance of preferred stock		$ 1,300,000
Preferred stock redemption price per share	$ 25.00		$ 25.00
Two Public Preferred Stock Offerings [Member]
Number of stock shares issued during the period	255,000
Net proceeds from issuance of preferred stock	$ 5,600,000
Cumulative preferred stock dividend per share	$ 2.75

XML 55 R44.htm IDEA: XBRL DOCUMENT

Related Parties (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Related Parties (Details Narrative) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Operating leases, rent expense	$ 237,000	$ 202,000	$ 690,000	$ 581,000
Accrued liability to related party	16,614		16,614		$ 16,626
Kashmir Air, Inc [Member]
Operating leases, rent expense	32,000	32,000	96,000	96,000
Accrued liability to related party	17,000		17,000		17,000
Physician [Member]
Revenues	4,000	5,000	12,000	13,000
Receivable balance due from this customer	1,500		1,500		1,600
Chief Executive Officer [Member]
Operating leases, rent expense	47,000	$ 43,000	141,000	$ 131,000
Security deposit	13,000		13,000		$ 13,000
Prepaid rent	$ 12,000		$ 12,000

XML 56 R45.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended	9 Months Ended
Stock-Based Compensation (Details Narrative) - USD ($)	Apr. 30, 2017	Aug. 31, 2017	May 31, 2017	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2016	Apr. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Liability for cash-settled awards				$ 17,000	$ 17,000	$ 31,000
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of shares issued			1,000,000		1,000,000
Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of shares issued		60,195
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Restricted shares granted to outside members of the Board of Directors					528,000
Unvested stock option award, equity				548,334	548,334
Unvested stock option award, liability				30,135	30,135
2014 Equity Incentive Plan [Member] \| Employees Officers Directors and Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized							1,351,000
2014 Equity Incentive Plan [Member] \| Board of Directors [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Restricted shares granted to outside members of the Board of Directors				200,000
2014 Equity Incentive Plan [Member] \| Three Executive Officers [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Restricted shares granted to outside members of the Board of Directors				300,000
Amended and Restated Equity Incentive Plan [Member] \| Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of shares issued	1,500,000
Share-based compensation arrangement by share-based payment award, number of shares available for grant				1,238,734	1,238,734
Amended and Restated Equity Incentive Plan [Member] \| Series A Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of shares issued	100,000
Amended and Restated Equity Incentive Plan [Member] \| Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares available for grant				67,000	67,000

XML 57 R46.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 125,819	$ 143,793	$ 333,854	$ 765,595
Direct Operating Costs [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	1,705	3,571	7,162	8,909
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	124,789	131,077	318,870	731,690
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	(675)	3,767	7,822	6,910
Selling and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense		$ 5,378		$ 18,086

XML 58 R47.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2017 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding and unvested at beginning	406,959
Granted	528,000
Vested	(327,159)
Forfeited	(29,331)
Outstanding and unvested at ending	578,469

XML 59 R48.htm IDEA: XBRL DOCUMENT

Restructuring Charges (Details Narrative) - USD ($)	3 Months Ended			9 Months Ended
Restructuring Charges (Details Narrative) - USD ($)	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Restructuring Charges Details Narrative
Restructuring charges		$ 276,000		$ 275,628
Accrued restructuring charges	$ 19,000			$ 19,000

XML 60 R49.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments (Details Narrative) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability, current and long term portion	$ 537,736	$ 535,477
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value		7,300,000
Fair Value, Input, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability, current and long term portion	670,000	930,000
Opus Debt [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Line of credit	$ 2,000,000	$ 2,000,000

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

XML 61 R50.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Fair Value, Input, Level 3 [Member] - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, beginning	$ 929,549	$ 1,172,508
Acquisitions		678,368
Change in fair value	151,423	(607,978)
Settlement in the form of shares issued	(331,676)
Payments	(79,603)	(153,799)
Balance, ending	$ 669,693	$ 1,089,099

XML 62 R51.htm IDEA: XBRL DOCUMENT

Subsequent Event (Details Narrative) - USD ($)	1 Months Ended
Subsequent Event (Details Narrative) - USD ($)	Oct. 31, 2017	Sep. 30, 2017
Opus Credit Facility [Member]
Revolving line of credit		$ 2,000,000
Subsequent Event [Member] \| SVB Debt Agreement [Member]
Payment of fees	$ 90,000
Number of warrants to purchase shares of common stock	125,000
Payments for annual anniversary fee	$ 50,000
Subsequent Event [Member] \| Opus Credit Facility [Member]
Revolving line of credit	$ 5,000,000
Unsecured portion of credit line fee, percentage	0.50%
Secured revolving line of credit percentage	200.00%
Percentage of shares in offshore facilities	65.00%
Subsequent Event [Member] \| Opus Credit Facility [Member] \| Prime Rate [Member]
Revolving line of credit, interest rate - Prime plus	1.75%

EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 64 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 126 240 1 true 53 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://mtbc.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited Sep 30, 2017) Sheet http://mtbc.com/role/BalanceSheetsUnauditedSep302017 Condensed Consolidated Balance Sheets (Unaudited Sep 30, 2017) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited Sep 30, 2017) (Parenthetical) Sheet http://mtbc.com/role/BalanceSheetsUnauditedSep302017Parenthetical Condensed Consolidated Balance Sheets (Unaudited Sep 30, 2017) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://mtbc.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://mtbc.com/role/StatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statement of Shareholders' Equity (Unaudited) Sheet http://mtbc.com/role/StatementOfShareholdersEquity Condensed Consolidated Statement of Shareholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://mtbc.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Organization and Business Sheet http://mtbc.com/role/OrganizationAndBusiness Organization and Business Notes 8 false false R9.htm 00000009 - Disclosure - Liquidity Sheet http://mtbc.com/role/Liquidity Liquidity Notes 9 false false R10.htm 00000010 - Disclosure - Basis of Presentation Sheet http://mtbc.com/role/BasisOfPresentation Basis of Presentation Notes 10 false false R11.htm 00000011 - Disclosure - Acquisitions Sheet http://mtbc.com/role/Acquisitions Acquisitions Notes 11 false false R12.htm 00000012 - Disclosure - Goodwill and Intangible Assets-Net Sheet http://mtbc.com/role/GoodwillAndIntangibleAssets-net Goodwill and Intangible Assets-Net Notes 12 false false R13.htm 00000013 - Disclosure - Net Loss Per Common Share Sheet http://mtbc.com/role/NetLossPerCommonShare Net Loss Per Common Share Notes 13 false false R14.htm 00000014 - Disclosure - Debt Sheet http://mtbc.com/role/Debt Debt Notes 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingencies Sheet http://mtbc.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Shareholders' Equity Transactions Sheet http://mtbc.com/role/ShareholdersEquityTransactions Shareholders' Equity Transactions Notes 16 false false R17.htm 00000017 - Disclosure - Related Parties Sheet http://mtbc.com/role/RelatedParties Related Parties Notes 17 false false R18.htm 00000018 - Disclosure - Stock-Based Compensation Sheet http://mtbc.com/role/Stock-basedCompensation Stock-Based Compensation Notes 18 false false R19.htm 00000019 - Disclosure - Income Taxes Sheet http://mtbc.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 00000020 - Disclosure - Restructuring Charges Sheet http://mtbc.com/role/RestructuringCharges Restructuring Charges Notes 20 false false R21.htm 00000021 - Disclosure - Fair Value of Financial Instruments Sheet http://mtbc.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 21 false false R22.htm 00000022 - Disclosure - Subsequent Event Sheet http://mtbc.com/role/SubsequentEvent Subsequent Event Notes 22 false false R23.htm 00000023 - Disclosure - Acquisitions (Tables) Sheet http://mtbc.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://mtbc.com/role/Acquisitions 23 false false R24.htm 00000024 - Disclosure - Goodwill and Intangible Assets-Net (Tables) Sheet http://mtbc.com/role/GoodwillAndIntangibleAssets-netTables Goodwill and Intangible Assets-Net (Tables) Tables http://mtbc.com/role/GoodwillAndIntangibleAssets-net 24 false false R25.htm 00000025 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://mtbc.com/role/NetLossPerCommonShareTables Net Loss Per Common Share (Tables) Tables http://mtbc.com/role/NetLossPerCommonShare 25 false false R26.htm 00000026 - Disclosure - Commitments and Contingencies (Tables) Sheet http://mtbc.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://mtbc.com/role/CommitmentsAndContingencies 26 false false R27.htm 00000027 - Disclosure - Stock-Based Compensation (Tables) Sheet http://mtbc.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://mtbc.com/role/Stock-basedCompensation 27 false false R28.htm 00000028 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://mtbc.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://mtbc.com/role/FairValueOfFinancialInstruments 28 false false R29.htm 00000029 - Disclosure - Organization and Business (Details Narrative) Sheet http://mtbc.com/role/OrganizationAndBusinessDetailsNarrative Organization and Business (Details Narrative) Details http://mtbc.com/role/OrganizationAndBusiness 29 false false R30.htm 00000030 - Disclosure - Liquidity (Details Narrative) Sheet http://mtbc.com/role/LiquidityDetailsNarrative Liquidity (Details Narrative) Details http://mtbc.com/role/Liquidity 30 false false R31.htm 00000031 - Disclosure - Acquisitions (Details Narrative) Sheet http://mtbc.com/role/AcquisitionsDetailsNarrative Acquisitions (Details Narrative) Details http://mtbc.com/role/AcquisitionsTables 31 false false R32.htm 00000032 - Disclosure - Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details) Sheet http://mtbc.com/role/Acquisitions-ScheduleOfBusinessAcquisitionsByAcquisitionDetails Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details) Details 32 false false R33.htm 00000033 - Disclosure - Acquisitions - Business Acquisition, Pro Forma Information (Details) Sheet http://mtbc.com/role/Acquisitions-BusinessAcquisitionProFormaInformationDetails Acquisitions - Business Acquisition, Pro Forma Information (Details) Details 33 false false R34.htm 00000034 - Disclosure - Goodwill and Intangible Assets-Net (Details Narrative) Sheet http://mtbc.com/role/GoodwillAndIntangibleAssets-netDetailsNarrative Goodwill and Intangible Assets-Net (Details Narrative) Details http://mtbc.com/role/GoodwillAndIntangibleAssets-netTables 34 false false R35.htm 00000035 - Disclosure - Goodwill and Intangible Assets-Net - Schedule of Intangible Assets and Goodwill (Details) Sheet http://mtbc.com/role/GoodwillAndIntangibleAssets-net-ScheduleOfIntangibleAssetsAndGoodwillDetails Goodwill and Intangible Assets-Net - Schedule of Intangible Assets and Goodwill (Details) Details 35 false false R36.htm 00000036 - Disclosure - Goodwill and Intangible Assets-Net - Schedule of Finite-Lived Intangible Assets (Details) Sheet http://mtbc.com/role/GoodwillAndIntangibleAssets-net-ScheduleOfFinite-livedIntangibleAssetsDetails Goodwill and Intangible Assets-Net - Schedule of Finite-Lived Intangible Assets (Details) Details 36 false false R37.htm 00000037 - Disclosure - Goodwill and Intangible Assets-Net - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) Sheet http://mtbc.com/role/GoodwillAndIntangibleAssets-net-ScheduleOfFinite-livedIntangibleAssetsFutureAmortizationExpenseDetails Goodwill and Intangible Assets-Net - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) Details 37 false false R38.htm 00000038 - Disclosure - Net Loss Per Common Share (Details Narrative) Sheet http://mtbc.com/role/NetLossPerCommonShareDetailsNarrative Net Loss Per Common Share (Details Narrative) Details http://mtbc.com/role/NetLossPerCommonShareTables 38 false false R39.htm 00000039 - Disclosure - Net Loss Per Common Share - Schedule of Losses Per Share, Basic and Diluted (Details) Sheet http://mtbc.com/role/NetLossPerCommonShare-ScheduleOfLossesPerShareBasicAndDilutedDetails Net Loss Per Common Share - Schedule of Losses Per Share, Basic and Diluted (Details) Details 39 false false R40.htm 00000040 - Disclosure - Debt (Details Narrative) Sheet http://mtbc.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://mtbc.com/role/Debt 40 false false R41.htm 00000041 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://mtbc.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://mtbc.com/role/CommitmentsAndContingenciesTables 41 false false R42.htm 00000042 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details) Sheet http://mtbc.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancelableOperatingLeasesDetails Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details) Details 42 false false R43.htm 00000043 - Disclosure - Shareholders' Equity Transactions (Details Narrative) Sheet http://mtbc.com/role/ShareholdersEquityTransactionsDetailsNarrative Shareholders' Equity Transactions (Details Narrative) Details http://mtbc.com/role/ShareholdersEquityTransactions 43 false false R44.htm 00000044 - Disclosure - Related Parties (Details Narrative) Sheet http://mtbc.com/role/RelatedPartiesDetailsNarrative Related Parties (Details Narrative) Details http://mtbc.com/role/RelatedParties 44 false false R45.htm 00000045 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://mtbc.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://mtbc.com/role/Stock-basedCompensationTables 45 false false R46.htm 00000046 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) Sheet http://mtbc.com/role/Stock-basedCompensation-ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails Stock-Based Compensation - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) Details 46 false false R47.htm 00000047 - Disclosure - Stock-Based Compensation - Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) Sheet http://mtbc.com/role/Stock-basedCompensation-DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails Stock-Based Compensation - Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) Details 47 false false R48.htm 00000048 - Disclosure - Restructuring Charges (Details Narrative) Sheet http://mtbc.com/role/RestructuringChargesDetailsNarrative Restructuring Charges (Details Narrative) Details http://mtbc.com/role/RestructuringCharges 48 false false R49.htm 00000049 - Disclosure - Fair Value of Financial Instruments (Details Narrative) Sheet http://mtbc.com/role/FairValueOfFinancialInstrumentsDetailsNarrative Fair Value of Financial Instruments (Details Narrative) Details http://mtbc.com/role/FairValueOfFinancialInstrumentsTables 49 false false R50.htm 00000050 - Disclosure - Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) Sheet http://mtbc.com/role/FairValueOfFinancialInstruments-FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails Fair Value of Financial Instruments - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) Details 50 false false R51.htm 00000051 - Disclosure - Subsequent Event (Details Narrative) Sheet http://mtbc.com/role/SubsequentEventDetailsNarrative Subsequent Event (Details Narrative) Details http://mtbc.com/role/SubsequentEvent 51 false false All Reports Book All Reports mtbc-20170930.xml mtbc-20170930.xsd mtbc-20170930_cal.xml mtbc-20170930_def.xml mtbc-20170930_lab.xml mtbc-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 69 0001493152-17-012483-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-17-012483-xbrl.zip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